



(86) Date de dépôt PCT/PCT Filing Date: 2010/03/26

(87) Date publication PCT/PCT Publication Date: 2010/11/04

(45) Date de délivrance/Issue Date: 2016/03/29

(85) Entrée phase nationale/National Entry: 2011/09/23

(86) N° demande PCT/PCT Application No.: CN 2010/071357

(87) N° publication PCT/PCT Publication No.: 2010/124547

(30) Priorité/Priority: 2009/03/26 (US61/163,863)

(51) Cl.Int./Int.Cl. *C12N 9/78* (2006.01),
A61K 38/50 (2006.01), *A61K 47/48* (2006.01),
A61P 31/12 (2006.01), *A61P 35/00* (2006.01),
C12N 15/00 (2006.01), *C12N 15/55* (2006.01),
C12N 9/96 (2006.01), *C12N 11/08* (2006.01)


(72) Inventeurs/Inventors:
LEUNG, THOMAS YUN-CHUNG, CN;
LO, THOMAS WAI-HUNG, CN

(73) Propriétaire/Owner:
THE HONG KONG POLYTECHNIC UNIVERSITY, CN

(74) Agent: GOWLING LAFLEUR HENDERSON LLP

(54) Titre : PEGYLATION DIRIGEE CONTRE UN SITE D'ARGINASES ET SON UTILISATION EN TANT QU'AGENTS
ANTICANCEREUX ET ANTIVIRAUX

(54) Title: SITE-DIRECTED PEGYLATION OF ARGINASES AND THE USE THEREOF AS ANTI-CANCER AND ANTI-
VIRAL AGENTS



(57) Abrégé/Abstract:

Mono-pegylated arginase conjugate and method producing thereof. The mono-pegylated arginase is homogeneous in molecular weight and shows therapeutic effect for treating cancers and viral infections. The method of producing such arginase conjugate has a main step of genetically modifying the gene encoding an arginase so that the PEG moiety can attach to the enzyme at a predetermined, specific intended site. This is achieved by removing the PEG attaching amino acid residues at undesirable sites while keeping (or adding, if necessary) the one at the desirable site of the enzyme. Two exemplary mono-pegylated arginase conjugates so produced are human arginase I (HAI) where a polyethylene glycol (PEG) moiety is site-specific covalently bonded to Cys⁴⁵ of the enzyme and *Bacillus caldovelox* arginase (BCA) where a polyethylene glycol (PEG) moiety is site-specific covalently bonded to Cys¹⁶¹ of the enzyme.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
4 November 2010 (04.11.2010)(10) International Publication Number
WO 2010/124547 A1

PCT

(51) International Patent Classification:

A61K 38/43 (2006.01) *A61P 31/00* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/CN2010/071357

(22) International Filing Date:

26 March 2010 (26.03.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/163,863 26 March 2009 (26.03.2009) US

(71) Applicant (for all designated States except US): **THE HONG KONG POLYTECHNIC UNIVERSITY** [CN/CN]; Hung Hom, Hong Kong (CN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LEUNG, Thomas, Yun-Chung** [CN/CN]; Room Y802, 8/F, Block Y, Department of Applied Biology & Chemical Technology, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong (CN). **LO, Thomas, Wai-Hung** [CN/CN]; Room Y802, 8/F, Block Y, Department of Applied Biology & Chemical Technology, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong (CN).(74) Agent: **SCIHEAD PATENT AGENT CO., LTD**; Room 1508, Huihua Commercial & Trade Building, No. 80 Xi-anliezhong Road, Yuexiu, Guangzhou, Guangdong 510070 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— with international search report (Art. 21(3))

[Continued on next page]

(54) Title: SITE-DIRECTED PEGYLATION OF ARGINASES AND THE USE THEREOF AS ANTI-CANCER AND ANTI-VIRAL AGENTS

FIG. 4a

(57) Abstract: Mono-pegylated arginase conjugate and method producing thereof. The mono-pegylated arginase is homogeneous in molecular weight and shows therapeutic effect for treating cancers and viral infections. The method of producing such arginase conjugate has a main step of genetically modifying the gene encoding an arginase so that the PEG moiety can attach to the enzyme at a predetermined, specific intended site. This is achieved by removing the PEG attaching amino acid residues at undesirable sites while keeping (or adding, if necessary) the one at the desirable site of the enzyme. Two exemplary mono-pegylated arginase conjugates so produced are human arginase I (HAI) where a polyethylene glycol (PEG) moiety is site-specific covalently bonded to Cys⁴⁵ of the enzyme and *Bacillus caldovelox* arginase (BCA) where a polyethylene glycol (PEG) moiety is site-specific covalently bonded to Cys¹⁶¹ of the enzyme.

WO 2010/124547 A1

WO 2010/124547 A1



— *with sequence listing part of description (Rule 5.2(a))*

SITE-DIRECTED PEGYLATION OF ARGINASES AND THE USE THEREOF AS ANTI-CANCER AND ANTI-VIRAL AGENTS

CROSS REFERENCE

[1] This application claims benefit from United States Provisional Patent Application Number 61/163,863, filed March 26, 2009.

FIELD OF THE INVENTION

[2] The present invention relates to the modification of an arginase for the purpose of increasing the enzyme's serum or circulating half-life and improving its pharmacokinetic properties, *in vivo* biological activity, stability, and reducing the immune reaction (immunogenicity) to the enzyme *in vivo*. More specifically, the invention relates to the site-specific covalent conjugation of monopolyethylene glycol to the arginase through genetically modifying the gene encoding the enzyme to produce mono- and site-specific, pegylated arginase, which become effective means of a number of arginine-dependent diseases, such as, for example, various cancers and human immunodeficiency virus (HIV) infection.

BACKGROUND OF THE INVENTION

Arginase

[3] Arginase is a manganese metalloenzyme containing a metal-activated hydroxide ion, a critical nucleophile in metalloenzymes that catalyze hydrolysis or hydration reactions. Arginase converts naturally occurring arginine into ornithine and urea. The enzyme exists in many living organisms, including bacteria and humans (Jenkinson et al., 1996, Comp Biochem Physiol B Biochem Mol Biol, 114:107-32).

Pegylation of Arginase

[4] Arginase may be used as therapeutic agent and administered parenterally for various indications. However, parenterally administrated arginase, which is a protein, may be immunogenic and have a short pharmacological half-life. Consequently, it can be difficult to achieve therapeutically useful blood levels of the proteins in patients. These problems may be overcome by conjugating the proteins to polymers such as polyethylene glycol (PEG).

[5] Covalent attachment of the inert, non-toxic, biodegradable polymer PEG, to molecules has important applications in biotechnology and medicine. Pegylation of biologically and pharmaceutically active proteins has been reported to improve pharmacokinetics, resulting in sustained duration, improve safety (e.g. lower toxicity, immunogenicity and antigenicity), increase efficacy, decrease dosing frequency, improve drug solubility and stability, reduce proteolysis, and facilitate controlled drug release (Roberts et al., 2002, Adv Drug Deliv Rev, 54:459-76; Harris & Chess, 2003, Nat Rev Drug Discov, 2:214-221).

[6] PEG -protein conjugates produced by conventional methods in the art contain heterogeneous species, each being attached with a variable number of PEG molecules, ranging from zero to the number of amino groups that the protein has. Even for species that has the same number of PEG molecule attached, the site of attachment on the protein may vary from species to species. Such non-specific pegylation, however, can result in conjugates that are partially or virtually inactive. Reduction of activity may be caused by shielding the protein's active receptor binding domain when the PEG is attached at a improper site. Thus, there is a clear need for a better way of producing homogeneously pegylated protein molecules which retain the activity of the parent protein and making possible the administration of correct and consistent dosages necessary for clinical uses.

Cancer Treatment via Amino Acid Deprivation

[7] Amino acid deprivation therapy is an effective means for the treatment of some cancers. Although normal cells do not require arginine, many cancer cell lines are auxotrophic for this amino acid. Many lines of evidence have shown that *in vitro* arginine depletion, either with an arginine-degrading enzyme or using arginine-deficient medium, leads to rapid destruction of a wide range of cancer cells (Scott et al., 2000, Br J Cancer, 83:800-10). But direct use of enzymes, which are proteins, has problems of immunogenicity, antigenicity and short circulating half-life.

Inhibition of Virus by Arginine Deprivation

[8] Viral infections are among the leading causes of death with millions of deaths each year being directly attributable to several viruses including hepatitis and human immunodeficiency virus (HIV). However, there are several problems with current anti-viral therapies. First, there are relatively few effective antiviral drugs. Many of the existing anti-virals cause adverse or undesirable side-effects. Most effective therapies (such as vaccination) are highly specific for only a single strain of virus. Frequently the virus undergoes mutation such that it becomes resistant to either the drug or vaccine. There is a need for methods for inhibiting viral replication which do not have the problems associated with the prior art.

[9] Many studies over the last 30 years have demonstrated that extracellular arginine is required for viral replication *in vitro*. Historically this has been accomplished by making tissue culture media deficient in arginine and dialyzing the serum used as a supplement in order to achieve arginine free medium. Using this methodology to achieve arginine deprivation results in inhibition of replication of a large number of diverse families of viruses including: adeno virus (Rouse et al., 1963, Virology, 20:357-365), herpes virus (Tankersley, 1964, J Bacteriol, 87: 609-13).

Human Immunodeficiency Virus (HIV)

[10] Acquired immune deficiency syndrome (AIDS) is a fatal disease, reported

cases of which have increased dramatically within the past several years. The AIDS virus was first identified in 1983. It has been known by several names and acronyms. It is the third known T-lymphotropic virus (HTLV-III), and it has the capacity to replicate within cells of the immune system, causing profound cell destruction. The AIDS virus is a retrovirus, a virus that uses reverse transcriptase during replication. Two distinct families of HIV have been described to date, namely HIV-1 and HIV-2. The acronym "HIV" is used herein to refer to human immunodeficiency viruses generically. HIV replication is believed to be arginine-dependent, depletion of which would thus inhibit HIV replication.

SUMMARY OF THE INVENTION

[11] One object of the present invention is to provide novel PEG-arginase conjugates substantially homogeneous and having a PEG moiety covalently bound to a specific site at the arginase molecule. Two preferred embodiments of the present invention are Cys⁴⁵-human arginase I (HAI) and Cys¹⁶¹-*Bacillus caldovelox* arginase (BCA).

[12] Another object of the present invention is to provide a method of producing site-directed, mono-pegylated arginase conjugates, which have potent anti-cancer and anti-viral effects. One particular embodiment of the present invention comprises three general steps. The first step is a genetically modification of a gene encoding for an arginase so that the resulting arginase will have a single free cysteine residue at a given position. The second step is expressing the modified gene in a chosen system to produce desired arginase. The expressing system may be human cells or issues, or other organisms including, for example, a bacterial cell, a fungal cell, a plant cell, an animal cell, an insect cell, a yeast cell, or a transgenic animal. The third step is conjugation between the free cysteine residue of the arginase and a maleimide group (MAL) of PEG compound, resulting in a covalent bond between the PEG compound and the free cysteine of the arginase.

[13] Another object of the present invention is to provide a method of treating viral infection via arginine depletion. This treating method employs homogeneous monopegylated arginase to inhibit viruses' replication.

[14] Another object of the present invention is to provide a method of anti-human immunodeficiency virus (HIV). This method employs homogeneous monopegylated arginase to inhibit HIV's replication.

[15] Another object of the present invention is to provide a method of enhancing arginase's enzymatic activity by replacing the valine at position 20 of *Bacillus caldovelox* arginase (or the corresponding position in HAI and other arginases) with another amino acid residue, for example, proline.

[16] Still another object of the present invention is to provide a method of enhancing arginase's enzymatic activity, which is accomplished by replacing the native metal cofactor manganese with cobalt.

[17] The various features of novelty which characterize the invention are pointed out with particularity in the claims annexed to and forming a part of this disclosure. For a better understanding of the invention, its operating advantages, and specific objects attained by its use, reference should be made to the drawings and the following description in which there are illustrated and described preferred embodiments of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

[18] FIG. 1 shows the nucleotide sequence of human arginase I (a) (SEQ ID No: 1), its mutated nucleotide sequence designed for site-directed pegylation (b) (SEQ ID No: 2) according to the present invention, the nucleotide sequence of *Bacillus caldovelox* arginase (c) (SEQ ID No: 3), and its mutated nucleotide sequence designed for site-directed pegylation (d) (SEQ ID No: 4) according to the present invention.

[19] FIG. 2 shows the amino acid sequence of human arginase I (a) (SEQ ID No: 5), its modified amino acid sequence designed for Cys⁴⁵ site-directed pegylation (b) (SEQ ID No: 6) according to the present invention, the amino acid sequence of *Bacillus caldovelox* arginase (c) (SEQ ID No: 7), and its modified amino acid sequence designed for Cys¹⁶¹ site-directed pegylation (d) (SEQ ID No: 8) according to the present invention.

[20] FIG. 3 shows the nucleotide and amino acid sequences of the human arginase I mutant (C168S/C303S) designed for Cys⁴⁵ site-directed pegylation (a) (SEQ ID No: 9 and 10), the alignment of the nucleotide and amino acid sequences of the 6xHis-tagged human arginase I mutant (C168S/C303S) designed for Cys⁴⁵ site-directed pegylation (b) (SEQ ID No: 11 and 12), the nucleotide and amino acid sequences of the *Bacillus caldovelox* arginase mutant (S161C) designed for Cys¹⁶¹ site-directed pegylation (c) (SEQ ID No: 13 and 14), and the alignment of the nucleotide and amino acid sequences of the 6xHis-tagged *Bacillus caldovelox* arginase mutant (S161C) designed for Cys¹⁶¹ site-directed pegylation (d) (SEQ ID No: 15 and 16).

[21] FIG. 4 shows (a) the crystal structure of the wild-type human arginase I (downloaded from NCBI website using Cn3D 4.1 software), showing that Cys⁴⁵ is far away from the active site; (b) the crystal structure of the wild-type *Bacillus caldovelox* arginase, showing that Ser¹⁶¹ is far away from the active site.

[22] FIG. 5 shows (a) the conjugation procedures for Cys⁴⁵-specific mono-pegylation of the 6xHis-tagged human arginase I mutant with a single chain mPEG-maleimide (20 kDa), showing that the double bond of a maleimide undergoes an alkylation reaction with a sulfhydryl group to form a stable thioether bond, and (b) the corresponding procedures for Cys¹⁶¹-specific mono-pegylation of the 6xHis-tagged *Bacillus caldovelox* arginase mutant.

[23] FIG. 6 depicts the time-course for fermentation in a 2-liter fermenter by the *E. coli* BL21-DE3 containing the arginase gene, showing the results obtained from the

batch fermentation (a1) and the results obtained from the fed-batch fermentation (a2); the history plots of the batch fermentation (b1) and the fed-batch fermentation (b2), showing the changes of parameters such as temperature, stirring rate, pH, dissolved oxygen values; the elution profile of the 6xHis-tagged human arginase I mutant from a chelating FF sepharose[®] column (c) with the first peak being protein impurities and the second peak being the purified human arginase I; and the elution profile of the 6xHis-tagged *Bacillus caldovelox* arginase mutant from a chelating FF sepharose[®] column (d) with the first peak being the protein impurities and the second peak being the purified *Bacillus caldovelox* arginase.

[24] FIG. 7 shows the SDS-PAGE analysis of different fractions involving 6xHis-tagged human arginase I mutant (a) and 6xHis-tagged *Bacillus caldovelox* arginase mutant (b).

[25] FIG. 8 shows (a) the SDS-PAGE analysis of the unpegylated human arginase I mutant and the Cys⁴⁵ pegylated human arginase I mutant (Lane 1: protein molecular weight marker, Lane 2: unpegylated human arginase I mutant, and Lane 3: Cys⁴⁵ pegylated human arginase I (HAI-PEG20)); (b) the SDS-PAGE analysis of unpegylated *Bacillus caldovelox* arginase mutant and the Cys¹⁶¹ pegylated *Bacillus caldovelox* arginase (Lane 1 :protein molecular weight marker; Lane 2: the unpegylated *Bacillus caldovelox* arginase mutant; and Lane 3: Cys¹⁶¹ pegylated *Bacillus caldovelox* arginase (BCA-PEG20)).

[26] FIG. 9 shows (a) the pharmacokinetic profiles of a single dose of non-pegylated and Cys⁴⁵ pegylated human arginase I (HAI-PEG20) injected intraperitoneally in BALB/c mice, and (b) the pharmacokinetic profiles of a single dose of non-pegylated and Cys¹⁶¹ pegylated *Bacillus caldovelox* arginase (BCA-PEG20) injected intraperitoneally in BALB/c mice.

[27] FIG. 10 shows (a) the pharmacodynamic profile of a single dose of Cys⁴⁵ pegylated human arginase I (HAI-PEG20) injected intraperitoneally in BALB/c mice

up to Day 14, and (b) the pharmacodynamic profile of a single dose of Cys¹⁶¹ pegylated *Bacillus caldovelox* arginase (BCA-PEG20) injected intraperitoneally in BALB/c mice up to Day 14.

[28] FIG. 11 shows the average body weights ($\pm$ s.e.m.) of BALB/c nude mice xenografted with Hep3B human liver cancer cells injected with different drugs (a); BALB/c nude mice xenografted with MCF-7 human breast cancer cells injected with Cys¹⁶¹ pegylated *Bacillus caldovelox* arginase (b); BALB/c nude mice xenografted with A549 lung cancer cells injected with different drugs.

[29] FIG. 12 shows (a) the *in vivo* activities (efficacies) of non-pegylated and Cys⁴⁵ pegylated human arginase I (HAI-PEG20) in BALB/c nude mice implanted with Hep3B human liver tumour cells subcutaneously; (b) the *in vivo* activities of Cys¹⁶¹ pegylated *Bacillus caldovelox* arginase (BCA-PEG20) in BALB/c nude mice xenografted with MCF-7 human breast cancer cells subcutaneously;

[30] FIG. 13 shows an HIV inhibition assay for Cys⁴⁵ pegylated human arginase I (HAI-PEG20).

- [31] FIG. 14 shows the HIV inhibition assay for azido-thymidine (AZT).
- [32] FIG. 15 shows the cytotoxicity of Cys⁴⁵ pegylated human arginase I (HAI-PEG20).
- [33] FIG. 16 shows a comparison of steady-state kinetics of human arginase I with different metal cofactors, i.e., Mn²⁺ and Co²⁺.
- [34] FIG. 17 shows a comparison of steady-state kinetics of the V20P mutant of *Bacillus caldovelox* arginase (BCA) and the wild-type BCA substituted with Mn²⁺ (BCAWTMn²⁺) or Co²⁺.

DETAILED DESCRIPTION OF PARTICULAR EMBODIMENTS OF THE INVENTION

Cloning of human arginase I gene (HAI)

[35] The gene sequence of human arginase I is shown in FIG. 1a (SEQ ID No: 1). The gene for 6xHis-tagged human arginase I (HAI) was generated by polymerase chain reaction (PCR) from the pAED4/HAI plasmid using the following oligonucleotides to generate an NdeI site at 5'-end and BamHI site at 3'-end. Primer HuAr07-F: 5' GAT.ATA.CAT.ATG.CAT.CAC.CAT.CAC 3' (SEQ ID NO: 17) and Primer HuAr08-R: 5' AGT.GCA.GGA.TCC.TTA.CTT.AGG.TGG.GTT.AAG.GTA.GTC 3' (SEQ ID NO:18). The PCR product was cut with NdeI and BamHI and subcloned into pET3a expression plasmid vector (Strategene).

[36] The pET3a *E. coli* expression plasmid vector contains a T7 promoter. The T7 promoter is positioned upstream from the gene 10 leader fragment. The correct sequence was confirmed by DNA sequencing the entire coding region for human arginase I (FIG 1a). This plasmid is referred to as pET3a/ HAI.

Cloning of *Bacillus caldovelox* arginase gene (BCA)

[37] The gene sequence of *Bacillus caldovelox* arginase is shown in FIG. 1c (SEQ ID No: 3). The gene for 6xHis-tagged *Bacillus caldovelox* arginase (BCA) was cut from

the pUC57/BCA plasmid using NdeI and BamHI restriction enzymes. The insert fragment was subcloned into pET3a expression plasmid vector (Stratagene).

[38] The correct sequence was confirmed by sequencing the entire coding region for *Bacillus caldovelox* arginase (FIG. 1c). This plasmid is referred to as pET3a/ BCA.

Mutagenesis of HAI

[39] The plasmid pET3a/HAI was used as a template for site-directed mutagenesis according to the QuikChange® site-directed mutagenesis kit (Stratagene). The codons for Cys¹⁶⁸ and Cys³⁰³ residues were mutated to the codons for Ser¹⁶⁸ and Ser³⁰³ respectively using the following mutagenic primers (SEQ ID No: 19, 20, 21, and 22, respectively).

Codon for Cys¹⁶⁸ mutated to codon for Ser¹⁶⁸:

Primer HuAr01-F: 5' GGG.TGA.CTC.CCT.CTA.TAT.CTG.CCA.AGG 3'

Primer HuAr02-R: 5' CCT.TGG.CAG.ATA.TAG.AGG.GAG.TCA.CCC 3'

Codon for Cys³⁰³ mutated to codon for Ser³⁰³

Primer HuAr03-F: 5' GCA.ATA.ACC.TTG.GCT.TCT.TTC.GGA.CTT.GC 3'

Primer HuAr04-R: 5' GCA.AGT.CCG.AAA.GAA.GCC.AAG.GTT.ATT.GC 3'.

[40] The mutated plasmid was transformed firstly into competent *E. coli* Top 10 cells. The sequence of mutated plasmid was confirmed by DNA sequencing. The gene sequence of HAI mutant designed for site-directed pegylation is shown in FIG. 1b(SEQ ID No: 2). The mutated plasmid was then transformed into *E. coli* BL21-DE3 cells for protein expression. The amino acid sequence of the wild-type HAI is shown in FIG. 2a(SEQ ID No: 5). The amino acid sequence of the C168S/C303S mutant is shown in FIG. 2b (SEQ ID No: 6), FIG. 3a (SEQ ID No: 10) and FIG. 3b (SEQ ID No: 12). As shown in FIG. 2b, two cysteine residues in human arginase I were replaced by serine residues. These two serine residues are underlined. The only

Cys present is Cys45. This mutant is called C168S/C303S, which only contains one single Cys residue (also underlined). Crystal structure of the wild-type HAI is shown in FIG. 4a. Based on this structure, the rational protein drug design for constructing the C168S/C303S mutant was made. In FIG. 2d, it is shown that one serine residue in *Bacillus caldovelox* arginase was replaced by cysteine residue. This cysteine residue is underlined. The 6xHis-tag region is also underlined and located at the C terminus. This mutant is called S161C.

Expression and purification of 6xHis-tagged arginases

[41] *E. coli* BL21-DE3 harboring the plasmid containing a mutated arginase gene encoding 6xHis-tagged human arginase I was grown overnight at 37°C in LB medium containing 80 µg/mL ampicillin. The inoculum was diluted 1:25 and grown to OD600 ~ 0.8 in a shake flask or the inoculum was diluted 1:10 and grown to OD600 ~ 15 in a fermentor. The cells were then induced with 0.4 mM IPTG for 4 hours. The bacterial cells were collected by centrifugation, resuspended in 50 mM Tris, 0.1 M NaCl, 10 mM MnCl₂, pH 7.4, and disrupted by high pressure homogenization.

[42] The 6xHis-tagged human arginase I was purified by a chelating FF sepharose[®] (GE Healthcare) column (5.0 cm x 9 cm; bed volume of 176 mL) equilibrated with Buffer A (0.02 M sodium phosphate, 0.5 M NaCl, pH 7.4). The 6xHis-tagged arginase were eluted with a gradient of 0.15 to 0.25 M imidazole (Fig. 6a & Fig. 6b). The flow rate was 20 mL/min. The fractions (Fig. 7a & Fig. 7b) containing purified arginase were collected. The yields of purified arginase were about 280 mg/L cell cultures.

[43] The exact procedure as described above for 6xHis-tagged human arginase I was repeated to obtain purified 6xHis-tagged *Bacillus caldovelox* arginase.

Site-directed pegylation of 6xHis-tagged arginases

[44] FIG. 5a shows the procedures for conjugating Cys⁴⁵-specific mono-pegylation

of the 6xHis-tagged human arginase I mutant with a single chain mPEG-maleimide (20 kDa), referred to as "HAI-PEG20". The double bond of a maleimide undergoes an alkylation reaction with a sulfhydryl group to form a stable thioether bond. FIG. 5b shows the conjugation procedures for Cys¹⁶¹-specific mono-pegylation of the 6xHis-tagged *Bacillus caldovelox* arginase mutant with a single chain mPEG-maleimide (20 kDa), referred to as "BCA-PEG20". One gram of 6xHis-tagged arginase was diafiltered into 0.02 M sodium phosphate, 0.5 M NaCl, pH 7.4, using Millipore Tangential Flow Filtration system (500 mL) with 10 K (cut-off) membrane (Millipore). The concentration of arginase was finally diluted to ~ 2 mg/mL. The reducing agent Tris(2-carboxyethyl)phosphine, TCEP, was added in a molar excess of 10 moles to one mole of arginase for reduction and the solution was gently stirred for 4 hours at room temperature. mPEG-Maleimide or mPEG-MAL (20 kDa) (Sunbright) in a molar excess of 20 moles to one mole of arginase was added to the reduced arginase and stirred for overnight at 4°C.

[45] The progress of site-directed pegylation was monitored by SDS-PAGE (FIG. 8a & 8b). Under the above described conditions, the free sulfhydryl group of cysteine at position 45 on human arginase I was specifically linked via a stable thioether bond to the activated maleimide group of mPEG-MAL (20 kDa). The final products of conjugation comprises predominantly Cys⁴⁵ pegylated human arginase I, unconjugated human arginase I, and mPEG-MAL (20 kDa). Similarly for *Bacillus caldovelox* arginase, the cysteine residue at position 161 was specifically linked via a stable thioether bond to the activated maleimide group of mPEG-MAL (20 kDa).

[46] The mPEG-MAL (20 kDa) pegylated arginase is advantageous over the mPEG-MAL (5 kDa) pegylated arginase in terms of a longer half-time and advantageous the mPEG-MAL (40 kDa) pegylated arginase in terms of a better solubility.

Batch Fermentation in a 2-Liter Fermenter

[47] The *E. coli* BL21-DE3 strain containing the arginase gene was stored at -80°C.

To prepare the seed inoculums for batch and fed-batch fermentation, 100 μ L frozen stock of the aforementioned strain were transferred into 250 mL flask containing 80 mL of fermentation medium. The bacterial culture was cultivated at 37°C and pH 7.0 in an orbital shaker rotating at 250 rpm. The cultivation was terminated when OD_{600nm} reached 5.5-6.0 at about 8-10 hours. The 12 mL (1%) seed inoculums was introduced into the 2-L fermenter containing 1200 mL autoclaved enriched fermentation medium. The batch fermentation was carried out at a temperature of 37°C. The pH was maintained at 7.0 by adding sodium hydroxide and hydrochloric acid. The dissolved oxygen level was controlled at above 30% air saturation by introducing air at 1-4 L/min and adjusting the stirring rate of the fermenter at 300-1200 rpm. Isopropyl-beta-D-thiogalacto-P (IPTG) 100 mM, inducer of the protein expression of *Bacillus caldovelox* arginase (BCA), was introduced into the fermentation broth to a final concentration of 0.5 mM when the OD_{600nm} was about 11.0 at 5 hours. After the IPTG induction, the fermentation was continued until 9 hours when the OD_{600nm} was about 16.4. The fermentation cells were harvested for separation and purification of BCA at 4 hours after IPTG induction. The aforementioned strain produced active BCA in an amount of about 105 mg/L of the fermentation medium. The time-course of the fermentation is plotted in FIG. 6a1. The history plot of this batch fermentation showing the changes of parameters such as temperature, stirring rate, pH and dissolved oxygen values is depicted in FIG. 6b1.

Fed-Batch Fermentation in a 2-L Fermenter

[48] The Fed-batch fermentation with high cell density culture was carried out at 37°C, pH 7.0 and dissolved oxygen was kept above 30% air saturation during the whole fermentation process. The procedure for preparing the seed inoculums was similar to that of the batch fermentation described above. The fermentation was initially started with batch cultivation strategy by introducing 5 mL (1%) seed

inoculums into the 2-L fermenter containing 500 mL autoclaved enriched fermentation medium. The dissolved oxygen decreased gradually to around 30% air saturation during the growth phase in batch cultivation period. Once the dissolved oxygen level increased above 80%, representing the depletion of carbon source, the PO₂ stat fed-batch strategy was started with the addition of feeding enriched medium. In this strategy, the feeding rate was adjusted to maintain the dissolved oxygen level below 60%, which provided minimal but adequate amount of carbon source during fermentation process. Isopropyl-beta-D-thiogalacto-P (IPTG) 100 mM was introduced into the fermentation broth to a final concentration of 0.5 mM when the OD_{600nm} was about 100 at 18 hours. After the IPTG induction, the fermentation was continued until 28 hours when the OD_{600nm} was about 186.8. The fermentation cells were harvested for separation and purification of BCA at 10 hours after IPTG induction. The aforementioned strain produced active BCA in an amount of about 1489.6 mg per liter of the fermentation medium, which is higher than all the other reported yields of different types of arginase. The time-course of the fermentation is plotted in FIG. 6a2. The history plot of this batch fermentation showing the changes of parameters such as temperature, stirring rate, pH and dissolved oxygen values is depicted in FIG. 6b2.

Comparison of Batch and Fed-Batch Fermentation

[49] Table 1 below compares the results of batch and fed-batch fermentation. The comparison demonstrates that the fed-batch fermentation is much superior to the batch operation in terms of culture OD₆₀₀, cell dry weight and yield of BCA per liter culture.

Table 1

	Batch fermentation	Fed-batch fermentation
Maximum OD ₆₀₀ reached	16.4	186.8
Cell dry weight (g)	4.9	76.6

yield of BCA (mg/L)	105.0	1489.6
yield of BCA (mg/g-cell)	21.4	19.4

Purification of site-directed pegylated arginases.

[50] Affinity nickel ion column chromatography was used to separate 6xHis-tagged site-directed pegylated arginases from mPEG-MAL (20 kDa) as described as follows. The final products of conjugation were loaded onto a chelating FF sepharose[®] (GE Healthcare) column (5.0 cm x 9 cm; bed volume of 176 mL) equilibrated with Buffer A (0.02 M sodium phosphate, 0.5 M NaCl, pH 7.4). The column was washed with 5 column volumes of Buffer A to remove free mPEG-MAL (20 kDa). The pegylated arginase was eluted using a salt gradient from 30% to 100% of Buffer B (0.02 M sodium phosphate, 0.5 M NaCl, 0.5 M imidazole, pH 7.4) for 5 column volumes. The protein content of the eluent was monitored at 280 nm wave length. The column was eluted at a flow rate of 20 mL/min and the pegylated arginase fractions were collected. The pooled fractions were diafiltered into PBS buffer (Gibco) and concentrated to 4-6 mg/mL. Before animal study, the endotoxin in the protein drug was removed using a Q-filter (Sartoris).

In vitro cytotoxicity of site-directed pegylated arginases

[51] In vitro cytotoxicity of Cys⁴⁵ pegylated human arginase I and Cys¹⁶¹ pegylated *Bacillus caldovelox* arginase were studied by standard MTT assay in different human cancer cells (melanoma, hepatocellular carcinoma, gastric adenocarcinoma, colorectal adenocarcinoma, pancreatic carcinoma, pancreatic adenocarcinoma, and T cell leukaemia).

[52] The known numbers of cells (5000) were incubated for 68 hr in each well of 96-well plate in a 5% CO₂ incubator at 37°C in the presence of different concentrations of Cys⁴⁵ pegylated human arginase I and Cys¹⁶¹ pegylated *Bacillus caldovelox* arginase. After 68 hr of drug incubation, 50 µg of the MTT (3-(4, 5-

Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a tetrazole) solution was added in each well and incubated for another 4 hr. The supernatant was discarded and 100 μ L of 10% SDS/0.01 M HCl was added in each well and then incubated overnight. The absorbance was recorded at 540 nm by a microplate reader (Bio-Rad). The concentration of each drug required to inhibit the 50% cell growth (IC_{50}) was determined for different cancer cell lines. Experiment was performed in triplicate.

[53] The IC_{50} values of Cys⁴⁵ pegylated human arginase I and Cys¹⁶¹ pegylated *Bacillus caldovelox* arginase for different cell lines were calculated and the results are listed in Table 2. As *Bacillus caldovelox* arginase was never known for anti-cancer response, it is thus the first time to have demonstrated its anti-cancer properties and efficacies. In various melanoma cell lines (SK-MEL-2, SK-MEL-28, A375), the IC_{50} values of Cys⁴⁵ pegylated human arginase I were lower when compared to those of Cys¹⁶¹ pegylated *Bacillus caldovelox* arginase. Among different hepatocellular carcinoma cell lines (HepG2, Hep3B, PLC/PRF/5), HepG2 cells were most sensitive to both Cys⁴⁵ pegylated human arginase I and Cys¹⁶¹ pegylated *Bacillus caldovelox* arginase. Taken together, all liver cancer (HCC) and melanoma cell lines tested were inhibited efficiently by BCA-PEG20 and HAI-PEG20.

[54] Cys¹⁶¹ pegylated *Bacillus caldovelox* arginase was also tested for the other five cancer cell lines including gastric adenocarcinoma, colorectal adenocarcinoma, pancreatic carcinoma, pancreatic adenocarcinoma, and T cell leukaemia. For gastric adenocarcinoma cell lines, the IC_{50} of Cys¹⁶¹ pegylated *Bacillus caldovelox* arginase for MKN-45 cells (0.798 U/mL) was similar to AGS cells (0.662 U/mL). Among different colorectal adenocarcinoma cell lines (WiDr, HT-29, SW1116), WiDr cells and HT-29 cells were sensitive to Cys¹⁶¹ pegylated *Bacillus caldovelox* arginase. When comparing the pancreatic carcinoma cell line (PANC-1) and the pancreatic adenocarcinoma cell line (BxPC-3), the IC_{50} of Cys¹⁶¹ pegylated *Bacillus caldovelox* arginase was lower in PANC-1 cells by four-fold. For T cell leukaemia cell line (Jurkat, Clone E6-1), the IC_{50}

of Cys¹⁶¹ pegylated *Bacillus caldovelox* arginase (0.41 U/mL) was also low when compared to the other cancer cell lines. Taken together, all cancer cell lines tested were sensitive to (and inhibited by) HAI-PEG20 and BCA-PEG20 treatments.

Table 2

Tumour	Cell line	<i>In vitro</i> IC ₅₀			
		Cys ⁴⁵ pegylated		Cys ¹⁶¹ pegylated	
		human arginase I		<i>Bacillus caldovelox</i> arginase	
		U/mL	µg/mL	U/mL	µg/mL
Melanoma	SK-MEL-2	0.079	0.80	0.612	11.25
	SK-MEL-28	0.064	0.65	0.910	16.72
	A375	0.088	0.90	0.15	2.76
Hepatocellular carcinoma	HepG2	0.097	0.99	2.002	36.79
	Hep3B	0.290	2.95	9.1	57.68
	PLC/PRF/5	0.94	9.56	2.376	43.67
Gastric adenocarcinoma	MKN-45		-----	0.798	14.67
	AGS		-----	0.662	12.17
Colorectal adenocarcinoma	WiDr	0.075	0.76	0.192	3.53
	HT-29		-----	0.220	4.04
	SW1116	0.41	4.18	1.515	27.84
Pancreatic carcinoma	PANC-1		-----	0.263	4.84
Pancreatic adenocarcinoma	BxPC-3		-----	0.846	15.54
T cell leukemia	Jurkat,		-----	0.410	7.54
	Clone E6-1				

Depletion of arginine by site-directed pegylated arginases

[55] Pharmacodynamics of Cys⁴⁵ pegylated human arginase I and Cys¹⁶¹ pegylated *Bacillus caldovelox* arginase were studied using BALB/c normal mice. The study was carried out in conjunction with the pharmacokinetic study (described below).

Therefore, the protocol remained the same. Again, the blood samples collected was centrifuged immediately at 13,200 rpm for 5 minutes and the plasma layer were collected for further analysis using the Amino Acid Analyzer (Biochrom 30,

Biochrom Ltd., England).

[56] As shown in FIG. 10a, ornithine level started to increase after the injection of Cys⁴⁵ pegylated human arginase I and stayed at a high level (>150 μ M) up to Day 3. Arginine was totally depleted starting from 6 hr (Day 0) and started to appear 6.8 $\pm$ 2.3 days after arginase administration. This indicated that HAI-PEG20 depleted blood arginine efficiently.

[57] For Cys¹⁶¹ pegylated *Bacillus caldovelox* arginase (BCA-PEG20), ornithine level also started to increase and stayed at a high level (>170 μ M) up to Day 3 (Fig. 10b). Arginine was totally depleted starting from 6 hr (Day 0) and started to appear 6.7 $\pm$ 2.1 days after arginase administration. This indicated that BCA-PEG20 depleted blood arginine efficiently.

[58] Both pegylated arginases (Cys⁴⁵ pegylated human arginase I and Cys¹⁶¹ pegylated *Bacillus caldovelox* arginase) displayed a similar pharmacodynamic profile.

In vivo anti-tumour efficacy on liver cancer

[59] *In vivo* anti-tumour efficacy of non-pegylated (HAI) and Cys⁴⁵ pegylated human arginase I (HAI-PEG20) on liver cancer was then studied.

[60] A number of BALB/c nude mice were injected with hepatocellular carcinoma Hep3B cells intraperitoneally (i.p.) and maintained *in vivo*. Then each of the 30 BALB/c nude mice was injected with $\sim 1 \times 10^6$ of the *in vivo* maintained cancer cells to the right axilla subcutaneously. When palpable tumours of 5 mm diameter were developed, the mice were separated into three different groups (see Table 3). Drugs or PBS buffer were administered intraperitoneally weekly starting on day 0 for 8 weeks. Body weights and tumour dimensions (L: length of the longer diameter and W: length of the shorter diameter of the tumour) were measured twice a week. Tumour volume ($1/2 \times L \times W^2$) was calculated and plotted against time. After 60 days or when tumour diameter reached 2.5 cm, the mice were euthanized. Survival rates

of the mice were recorded at the end of the study.

Table 3

<i>In vivo</i> anti-tumour activity protocol				
Group	Testing drug	Mice	Units/mouse	Route
1	PBS	5M5F	n/a	i.p.
2	Non-pegylated human arginase I	5M5F	500	i.p.
3	Cys ⁴⁵ pegylated human arginase I	5M5F	500	i.p.

[61] As shown in FIG. 11a, the average body weights of the PBS control group, the Cys⁴⁵ pegylated human arginase I group, and the non-pegylated human arginase I group were 25.9 ± 0.2 g, 25.0 ± 0.2 g, and 25.5 ± 0.2 g respectively, with no significant change throughout the experiment for each group.

[62] In terms of the tumour volume, Cys⁴⁵ pegylated human arginase I (HAI-PEG20) significantly reduced the rate of tumour growth starting from Day 47 compared to the PBS control group ($p < 0.01$); while non-pegylated human arginase I (HAI) did not show any significant effect ($p > 0.05$) (FIG. 12a).

In vivo anti-tumour efficacy on breast cancer

[63] *In vivo* anti-tumour efficacy of Cys¹⁶¹ pegylated *Bacillus arginase* (BCA-PEG20) on breast cancer was determined next.

[64] Athymic nude BALB/c mice (age of 6-8 weeks) were housed under sterile conditions with 12 hour light-dark cycle and provided with autoclaved feed ad libitum. The mice were acclimated for at least 1 week before the start of experiments. Each nude mouse was injected with 1×10^6 MCF-7 human breast cancer cells to the right axilla subcutaneously. When palpable tumours of 5 mm diameter were developed, the mice were randomly separated into two different groups (Table 4). Drugs or control vehicle (PBS) were injected intraperitoneally once per week starting

from Day 0. Tumour dimensions (L: longest diameter and W: its perpendicular diameter) and body weights were measured on every Mondays, Wednesdays and Fridays with Vernier caliper. Tumour volume was calculated with the formula ($1/2 \times L \times W^2$) and no. of fold increase in tumour volume was calculated with reference to Day 0. The results were plotted against time. At Day 18 or when tumour diameter reached 2.5 cm, the mice were euthanized and the final tumour and body weight were recorded.

Table 4

Group	<i>In vivo</i> anti-tumor activity protocol				Mice
	Testing drug	Units/mo use	route		
1	PBS (control)	N/A	i.p.		4M 4F
2	Cys ¹⁶¹ -pegylated <i>Bacillus caldovelox</i> arginase	250	i.p.		4M 4F

[65] As shown in FIG. 11b, no significant difference in average body weights of the control group (18.76 ± 0.50) and Cys¹⁶¹-pegylated *Bacillus caldovelox* arginase (19.76 ± 0.66) was observed throughout the experiment (Fig. 11b). Cys¹⁶¹-pegylated *Bacillus caldovelox* arginase significantly suppressed tumour growth and reduced the no. of fold increase in tumour volume in comparison to the PBS control group (2-way ANOVA: $p < 0.0001$, FIG. 12b). Using Bonferroni post-test, the reduction is statistically significant starting from Day 15 ($p < 0.01$) where the reduction is over 2.8 folds.

In vivo anti-tumour efficacy on lung cancer

[66] Athymic nude BALB/c mice (age of 6-8 weeks) were housed under sterile conditions with 12 hour light-dark cycle and provided with autoclaved feed ad libitum. The mice were acclimated for at least 1 week before the start of experiments.

Each nude mouse was injected with 5×10^6 A549 human lung cancer cells to the right axilla subcutaneously with matrigel growth supplement. When palpable tumours of ~5 mm diameter were developed, the mice were randomly separated into three different groups (Table 5). Drugs or control vehicle (PBS) were injected intraperitoneally once per week starting from Day 0. Tumour dimensions (L: longest diameter and W: its perpendicular diameter) and body weights were measured on every Mondays, Wednesdays and Fridays with Vernier caliper. Tumour volume was calculated with the formula $(1/2 \times L \times W^2)$ and no. of fold increase in tumour volume (relative tumour volume) was calculated with reference to Day 0.

Table 5

Group	In vivo anti-tumor activity protocol			
	Testing drug	Units/mouse	route	Mice
1	PBS (control)	N/A	i.p.	5M 5F
2	Unpegylated <i>Bacillus caldovelox</i>	250	i.p.	5M 5F
3	arginase Cys ¹⁶¹ -pegylated <i>Bacillus caldovelox</i> arginase	250	i.p.	5M 5F

[67] No significant difference in average body weights between different groups was observed throughout the experiment and last recorded as 23.98 ± 2.68 g for the control group, 23.68 ± 1.50 g for the unpegylated *Bacillus caldovelox* arginase and 23.16 ± 2.08 g for the Cys¹⁶¹-pegylated *Bacillus caldovelox* arginase at the end of experiment.

[68] Cys¹⁶¹-pegylated *Bacillus caldovelox* arginase (BCA-PEG20) however suppressed tumour growth significantly and statistically in comparison to vehicle control group in terms of progressive changes of tumour volume and no. of folds of tumour volume. Two-way ANOVA showed p values at < 0.0001 for both parameters while Bonferroni post-test indicated the difference to start from;

Day 28 ($p < 0.05$) to Day 35 ($p < 0.001$) for tumour volume and from Day 30 to Day 35 ($p < 0.01$ for all points) for relative tumour volume. The unpegylated *Bacillus caldovelox* arginase (BCA) at the same dose regime also showed anti-lung cancer effects in a similar extent with statistical significance for both parameters (two-way ANOVA, both with $p < 0.0001$).

In vivo anti-tumour efficacy on colorectal cancer

[69] *In vivo* anti-tumour efficacy of non-pegylated (BCA) and Cys¹⁶¹ pegylated *Bacillus caldovelox* arginase (BCA-PEG20) on colorectal cancer was determined as follows.

[70] Athymic nude BALB/c mice (age of 6-8 weeks) were housed under sterile conditions with 12 hour light-dark cycle and provided with autoclaved feed ad libitum. The mice were acclimated for at least 1 week before the start of experiments. Each nude mouse was implanted with $\sim 3 \text{ mm}^3$ of in vivo maintained HCT-15 human colorectal cancer cells to the right axilla subcutaneously. When stable palpable tumours of $\sim 5 \text{ mm}$ diameter were developed, the mice were randomly separated into five different groups (Table 6). Intraperitoneal administrations of arginase drugs or control vehicle (PBS) were given twice per week while 5-fluorouracil was given once per week starting from Day 0. Tumour dimensions (L: longest diameter and W: its perpendicular diameter) and body weights were measured on every Mondays, Wednesdays and Fridays with Vernier caliper. Tumour volume was calculated with the formula $(1/2 \times L \times W^2)$ and no. of fold increase in tumour volume (relative tumour volume) was calculated with reference to Day-0. The results were plotted against time. The mice were euthanized at the end of experiment or when tumour diameter reached 2.5 cm.

Table 6

In vivo anti-tumor activity protocol

Group	Testing drug	Units/mouse	route	Mice
1	PBS (control)	N/A	i.p.	4M 4F
2	Unpegylated <i>Bacillus caldovelox</i>	500	i.p.	4M 3F
3	arginase Cys ¹⁶¹ -pegylated <i>Bacillus caldovelox</i>	250	i.p.	4M 3F
4	arginase Cys ¹⁶¹ -pegylated <i>Bacillus caldovelox</i>	250	i.p.	4M 3F
5	arginase + 5-Fluorouracil 5-Fluorouracil	10 mg/kg	i.p.	2M 2F

[71] No significant difference in average body weights between different groups was observed throughout the experiment and last recorded as 24.3 ± 0.9 g for the control group, 22.1 ± 1.0 g for the unpegylated *Bacillus caldovelox* arginase group, 24.2 ± 0.7 g for the Cys¹⁶¹-pegylated *Bacillus caldovelox* arginase group, 23.5 ± 1.2 g for the Cys¹⁶¹-pegylated *Bacillus caldovelox* arginase + 5-fluorouracil group and 24.5 ± 1.4 g for the 5-fluorouracil group at the end of experiment.

[72] Both Cys¹⁶¹-pegylated *Bacillus caldovelox* arginase (BCA-PEG20) and unpegylated *Bacillus caldovelox* arginase (BCA) in all three arginase drugs treated groups suppressed tumour growth with statistical significance.

For the drug combination group (Cys¹⁶¹-pegylated *Bacillus caldovelox* arginase plus 5-fluorouracil), two-way ANOVA showed significance for no. of folds of tumour volume and tumour volume with $p < 0.0001$ in both cases. Bonferroni post-test further pinpointed the significant difference for no. of folds of tumour volume to be from Day 36 to Day 40. For Cys¹⁶¹-pegylated *Bacillus caldovelox* arginase alone group, two-way ANOVA showed significance for no. of folds of tumour volume and tumour volume with $p = 0.0005$ and $p = 0.0011$, respectively. Bonferroni post-test indicated the difference to be from Day 38 to Day 40 for no. of folds of tumour volume and on Day 40 for tumour volume. For unpegylated *Bacillus caldovelox* arginase group, the p values for no. of folds of tumour volume and tumour volume were 0.0202 and < 0.0001 , respectively. The 5-fluorouracil group did not show

significant tumour suppression in terms of no. of folds of tumour volume.

The drug combination group resulted in statistically significant lower tumour volume and no. of folds of tumour volume than both the Cys¹⁶¹-pegylated *Bacillus caldovelox* arginase alone group ($p < 0.0001$ and $p = 0.0120$, respectively) and the 5-fluorouracil alone group ($p = 0.0158$ and $p = 0.0434$, respectively). The results indicated a synergistic therapeutic effect for the Cys¹⁶¹-pegylated *Bacillus caldovelox* arginase and 5-fluorouracil.

In vivo inhibitory efficacy on breast cancer metastasis

[73] 1×10^5 cells of a mouse metastatic breast cancer cell line (4T1) were injected orthotopically into the No.4 inguinal mammary fat pad of wild-type BALB/c mice at the age of 6-8 weeks. When the tumors reached an average of 5 mm, the mice were divided into two different treatment groups (Table 7). BCA-PEG20 (250 U/mouse) or control vehicle (PBS) were injected intraperitoneally twice per week starting from Day 0. Body weight was measured every week. After three weeks, the mice were sacrificed and analyzed for the lung metastasis. The number of lung metastases was counted under a dissecting microscope after rinsing with PBS.

[74] No significant difference in averaged body weight between different groups was observed throughout the experiment and last recorded as 21.8 g for control group and 21.5 g for the BCA-PEG20 group at the end of experiment.

[75] Results demonstrate that BCA-PEG20 reduced the spontaneous lung tumor nodule formation compared with the PBS vehicle group. The spontaneous lung metastases were too numerous to count in PBS group but only 4 nodules on the average were found in the BCA-PEG20 treatment group (Table 8). The result demonstrates that arginine depletion by BCA-PEG20 inhibits breast tumor metastasis.

Table 7

In vivo anti-metastasis protocol

Group	Testing drug	Units/mouse	route	Mice
1	PBS (control)	N/A	i.p.	1M
2	BCA-PEG20	250	i.p.	2M

Table 8

Group	Testing drug	Spontaneous lung metastases
1	PBS (control)	TNTC*
2	BCA-PEG20	4

Effect on HIV (HAI-PEG20)

[76] The 50% inhibition concentration (IC_{50}) of the Cys⁴⁵ pegylated human arginase I (HAI-PEG20) on human immunodeficiency virus (HIV) was determined as a measure of its effect on HIV.

[77] The efficiency of an antiviral drug can be estimated using cell culture models for viral replication. The HIV replication assay utilizes H9 cells and HIV-1 strain RF. H9 cells, derived from human T lymphocytes, are highly susceptible to infection by CXCR4-using HIV-1 isolates, and show clear signs of cytopathic effects a few days post infection. HIV-1 strain RF is a CXCR4-using class B isolate that replicates to high levels in H9 cells.

[78] H9 cells were seeded in four 96-well plates at 5×10^4 viable cells/mL and the cultures incubated at 37°C. The following day, two 96-well plates were inoculated with HIV-1 at 0.005 multiplicity of infection (50 μ L per well).

[79] Twenty-four hours after infection, the cells of one infected 96-well plate were treated with the Cys⁴⁵ pegylated human arginase I (HAI-PEG20) diluted to a final concentration of 1 U/mL, 10 U/mL and 50 U/mL in tissue culture medium (10% RPMI). Eight replicates were tested for each drug concentration and 100 μ L were added per well.

[80] Azido-thymidine (AZT) was used as a benchmark drug for this assay to ensure that a dose response was obtained. This was diluted appropriately (0.01, 0.1 and 1 μ g/mL) in 10% RPMI and added to the second infected plate. Eight replicates were tested for each drug concentration and 100 μ L were added per well.

[81] A cytotoxicity control was set up in parallel; this consisted of one 96-well plate of uninfected cells treated with three drug concentrations (1 U/mL, 10 U/mL and 50 U/mL; 8 replicates per drug concentration). This would allow the cytotoxic concentration to be determined (CC_{50}).

[82] The remaining 96-well plate was inoculated with tissue culture medium alone to serve as the negative control.

[83] Five days post infection plates were examined for cytopathic effect and the IC_{50} of the drug determined by comparing syncytial cell number in drug treated and non-treated cells.

[84] The results show that H9 cells inoculated with HIV strain RF had viral infection, whereas H9 cells inoculated with tissue culture medium alone remained healthy throughout the study. Cytopathic effect was observed in the H9 cultures infected with HIV and treated with the Cys⁴⁵ pegylated human arginase I (HAI-PEG20) at all concentrations. Eight out of eight (8/8) infected wells treated with the pegylated enzyme at a final concentration of 1 U/mL, displayed cytopathic effect. For infected wells treated with the enzyme at a final concentration of 10 U/mL, 6/8 wells displayed cytopathic effect. When the drug was tested at the highest final

concentration of 50 U/mL, 3/8 wells displayed cytopathic effect. These results are shown in Table 9 and FIG. 13. The IC_{50} of the drug was found to be approximately 37 U/mL.

[85] When the benchmark drug AZT was added to infected wells at 0.01 μ g/mL, 7/8 wells displayed cytopathic effect. For infected wells treated with AZT at 0.1 μ g/mL, 6/8 wells displayed cytopathic effect and when tested at 1 μ g/mL, 2/8 wells displayed cytopathic effect. These results are illustrated in Fig. 14. The IC_{50} of the AZT was found to be 0.58 μ g/mL.

Table 9

Virus inhibition assay	
Sample	Results
HIV without Cys ⁴⁵ pegylated human arginase I treatment	24/24
HIV without Cys ⁴⁵ pegylated human arginase I treatment (second plate)	22/24
HIV treated with Cys ⁴⁵ pegylated human arginase I (50 U/mL)	3/8
HIV treated with Cys ⁴⁵ pegylated human arginase I (10 U/mL)	6/8
HIV treated with Cys ⁴⁵ pegylated human arginase I (1 U/mL)	8/8
HIV treated with AZT (0.01 μ g/mL)	7/8
HIV treated with AZT (0.1 μ g/mL)	6/8
HIV treated with AZT (1 μ g/mL)	2/8
Negative control	0/96
Cytotoxicity control – uninfected cells treated with Cys ⁴⁵ pegylated human arginase I (50 U/mL)	8/8*
Cytotoxicity control – uninfected cells treated with Cys ⁴⁵ pegylated human arginase I (10 U/mL)	8/8*
Cytotoxicity control – uninfected cells treated with Cys ⁴⁵ pegylated human arginase I (1 U/mL)	8/8*

Each well was inoculated with 50 μ L of HIV at 0.005 multiplicity of infection.

* = cytotoxicity observed in each well, therefore viability counts performed for 1 well for each concentration. The results are recorded as a ratio; e.g. 1/X, where 1 is the no. of positive wells/no. of wells inoculated.

[86] Table 10 presents the viability counts for the cytotoxicity control. In the

cytotoxicity test, all wells displayed symptoms of cytotoxicity, therefore viability counts were performed on one well for each concentration of Cys⁴⁵ pegylated human arginase I. The highest concentrations resulted in cell viabilities of 30% and 39% for 50 U/mL and 10 U/mL respectively. For 1 U/mL, cell viability was 58%. Based on this cell viability was assessed for all 8 wells and the average determined to be 48.9%. This approximates to a 50% reduction in cell viability based on the cell viability of cells (96.8%) when cells were seeded onto the 96 well plates. These results are displayed in Table 10 and FIG. 15, clearly demonstrating that HAI-PEG20 has inhibitory effects on HIV replication.

[87]

Table 10

Cell viability in cytotoxicity control				
Sample	Live cells	Total cells	Results	
			% viability	Average % viability
50 U/mL – 1 well	9	30	30	N/A
10 U/mL – 1 well	11	28	39	N/A
1 U/mL	well 1	19	33	48.9
	well 2	30	63	
	well 3	23	59	
	well 4	21	60	
	well 5	33	58	
	well 6	29	56	
	well 7	31	49	
	well 8	24	61	

N/A = not applicable

In vitro anti-cancer effects

[88] *In vitro* cancer cell culture studies on the anti-cancer efficacies of different arginine-depleting enzymes were conducted for various cancer types.

[89] *Cell Proliferation Assay*: For each cancer cell line, cells (5×10^3) in 100 μ L culture medium were seeded to the wells of a 96-well plate and incubated for 24 hours by

standard method. The culture medium was replaced with medium containing different concentrations of one of the arginases or arginine deiminase (ADI). The plates were incubated for an additional 3 days at 37°C in an atmosphere of 95% air/5% CO₂. The metabolically viable cell fraction was determined by the MTT assay, which was performed to estimate the number of viable cells in the culture. Non-linear regression with Prism 4.0 (Graphpad Software) was used to fit a sigmoidal dose response curve, and the amount of each of the arginine-degrading enzymes (in terms of U/mL or unit/ml or µg/mL) needed to achieve 50% inhibition of cell growth was defined as IC₅₀.

[90] *RT-PCR studies:* Total RNA was extracted from cancer cell lines grown in culture using the Qiagen RNeasy kit. For reverse transcription-polymerase chain reaction (RT-PCR), the RNA was first reverse-transcribed into cDNA by iScript cDNA Synthesis kit (Bio-Rad, CA) according to the manufacturer's instruction. Briefly, 5 µg of total RNA was subjected to RT at 42°C for 30 min. A 2 µL portion of cDNA was then amplified using 50 µL of reaction mixture containing 0.5 units of iTaq DNA polymerase (Bio-Rad, CA). PCR was performed in a DNA thermal MyCycler (Bio-Rad, CA). The following flanking primers were used:

[91] (a) Human ASS (448 bp product):

Sense: 5'-GGGGTCCCTGTGAAGGTGACC-3' ;

Anti-sense: 5'-CGTTCATGCTCACCAGCTC-3'

[92] (b) Human ASL (218 bp product):

Sense: 5'- CTCCTGATGACCCTCAAGGGA -3';

Anti-sense: 5'-CATCCCTTTGCGGACCAGGTA-3'

[93] (c) Human OTC (221 bp product):

Sense: 5'-GATTGGACACCCTGGCTAA-3';

Anti-sense: 5'-GGAGTAGCTGCCTGAAGGTG-3'

[94] (d) Human GAPDH (306 bp product):

Sense: 5'-AGCCACATCGCTCAGACA-3';

Anti-sense: 5'-GCCCAATACGACCAAATCC-3'

[95] The reaction products were subjected to 1% agarose gel electrophoresis. After electrophoresis and staining with ethidium bromide, all PCR product band intensities were analyzed by Lumi-Imager (Boehringer Mannheim, IN), and the relative mRNA expression levels were estimated by normalization with the house keeping gene GADPH.

[96] As the results indicate, arginases and ADI are all efficient arginine-degrading enzymes. Unexpectedly, we found that all the cancer cell lines tested here are sensitive to arginases but many cancer cell lines are actually resistant to ADI treatment. It was discovered in the present invention that this difference is due to the fact that arginase converts arginine to ornithine and urea while ADI converts it to citrulline and ammonia. Citrulline can be recycled back to arginine if the cancer cells are ASS-positive and ASL-positive, leading to drug resistance. Most strikingly, if the cancer cells are OTC-negative, they cannot recycle ornithine back to arginine in the cells even if they are ASS-positive and ASL-positive. This guideline provided by the present invention has been found to be consistent with all our data as well as data from other research groups. Under this guideline, for instance, if the cancer cells are either ASS-negative or ASL-negative or both, they would be arginase-sensitive and ADI-sensitive. On the other hand, if the cancer cells are both ASS-positive and ASL-positive but OTC-negative, they would be arginase-sensitive and ADI-resistant. Therefore, it is believed that that arginases have broader anti-cancer applications than ADI. Furthermore, ammonia (product from ADI reaction) is more toxic than urea (product from arginase reaction). Thus, the arginase anti-cancer agents of the

present invention are believed to be more safe than ADI.

[97] In vitro anti-cancer efficacy results are summarized in Tables 11a – 11g. As indicated in in Table 11a, all the melanoma cell lines tested were sensitive to arginase treatments. When arginase was added to culture medium, arginine was converted to ornithine and urea. All these cells were OTC-negative and according to the guideline discussed above, these cells cannot recycle the arginase reaction product ornithine back to arginine in the cells and therefore the cells are inhibited due to the lack of arginine. According to the IC_{50} values, all the arginases tested were very effective on the inhibition of cancer cell growth.

[98] Although all the melanoma cell lines tested were all ASS-positive and ASL-positive, the expression levels of ASS were low, which can be confirmed by performing an ASS activity assay. The low ASS expression level explains why these cell lines were all sensitive to ADI treatments. B16 is a mouse melanoma cell line and it is also sensitive to both arginases and ADI. Thus, it is believed that ADI kills the melanoma cells was due to the low level of ASS expression while arginases kill the melanoma cells because they are OTC-negative.

[99] In Table 11b, it is shown that all the leukemia cell lines tested were sensitive to arginase treatments. Some of these cancer cells tested were OTC-negative and according to the guideline discussed above, these cells cannot recycle the arginase reaction product ornithine back to arginine in the cells and therefore the cells are inhibited due to the lack of arginine. According to the IC_{50} values, all the arginases tested were very effective on inhibition of leukemia cancer cell growth. For ADI treatments, all the 4 leukemia cell lines tested were sensitive except the RPMI8226 cell line, which is resistant to ADI treatment, most likely due to the fact that it is both ASS-positive and ASL-positive. Therefore, for inhibiting leukaemia cells, arginases are advantageous over ADI.

[100] Table 11c shows that all the colorectal cancer cell lines tested were sensitive to

arginase treatments. All these cancer cells tested were OTC-negative. In consistent with the guideline discussed above, these cells cannot recycle the arginase reaction product ornithine back to arginine in the cells and therefore the cells are inhibited due to the lack of arginine. According to the IC_{50} values, all the arginases tested were very effective on the inhibition of colorectal cancer cell growth. For ADI treatments, only 2 colorectal cancer cell lines (WiDr and HT29) tested were sensitive and the other 2 (SW1116 and HCT15) were resistant to ADI treatment, most likely due to the fact that they are both ASS-positive and ASL-positive. For HT29, although it was ASS-positive and ASL-positive according to the RT-PCR data, the expression level of ASS was low, as confirmed by performing an ASS activity assay, which explains why this cell line was sensitive to ADI treatment.

[101] Also shown in Table 11c, most strikingly, all the pancreatic cancer cell lines tested were sensitive to arginase treatments. All these cancer cells tested were OTC-negative. As discussed above, these cells cannot recycle the arginase reaction product ornithine back to arginine in the cells and therefore the cells are inhibited due to the lack of arginine. According to the IC_{50} values, all the arginases tested were very effective on the inhibition of pancreatic cancer cell growth. For ADI treatments, only one pancreatic cancer cell line (Panc1) tested was sensitive and the other 2 (BxPC3 and HPAFII) were resistant to ADI treatment. Clearly, for inhibiting pancreatic cancer cells, arginases are better than ADI.

[102] Table 11d shows that all the gastric cancer cell lines tested were sensitive to arginase treatments. All these cancer cells tested were OTC-negative and thus, as discussed above, these cells cannot recycle the arginase reaction product ornithine back to arginine in the cells and therefore the cells are inhibited due to the lack of arginine. As the IC_{50} values indicate, all the arginases tested were very effective on the inhibition of gastric cancer cell growth. In a sharp contrast, all the gastric cancer cell lines tested were resistant to ADI treatment, most likely due to the fact that they

are both ASS-positive and ASL-positive. This similar result was obtained for the liver cancer (or HCC) cell lines tested as shown in Table 11e.

[103] Table 11e also shows that the retinoblastoma cancer cell line Y79 tested was sensitive to arginase treatments but resistant to ADI treatment, most likely due to the fact that they are both ASS-positive and ASL-positive.

[104] Table 11f shows that the lung cancer cell line A549 tested was sensitive to arginase treatments. These cancer cells tested were OTC-negative. It is also sensitive to ADI treatment, most likely due to the fact that they are either ASS-negative or ASL-negative. In contrast, also shown in Table 11f, all the cervical cancer cell lines tested were sensitive to arginase treatments (they were all OTC-negative), but only 2 cervical cancer cell line (SiHa and C-33A) tested were sensitive and the other 3 (HeLa, ME180, CC3) were resistant to ADI treatment, most likely due to the fact that they are both ASS-positive and ASL-positive.

[105] The results for breast cancer cells are shown in Table 11g. As it shows, all the breast cancer cell lines tested were sensitive to arginase treatments (they were all OTC-negative). Strikingly, only one breast cancer cell line (MDA-MB-231) tested was sensitive and the other 3 (MCF-7, ZR-75-1, Hs578T) were resistant to ADI treatments.

[106] Also shown in Table 11g are results for the prostate cancer cell line, which was found to be sensitive to both arginase and ADI treatments. As discussed above, such results can be explained by the fact that this cell line is both OTC-negative and ASS-negative.

Table 11a

Type of cancer	Cell line name (medium, source)	BCA U/mL ($\mu\text{g/mL}$)	HAI U/mL ($\mu\text{g/mL}$)	rhArg U/mL ($\mu\text{g/mL}$)	ADI U/mL ($\mu\text{g/mL}$)	ARG	OTC	ASS	ASL
melanoma	SK-mel-2	0.612	0.079	0.0556	0.0022	-	-	+	+

	(EMEM 10%FBS, 1%PS ATCC)	(11.25)	(0.80)	(1.31)	(0.082)			L	
	SK-mel-24 (EMEM 10%FBS, 1%PS NCI)			0.204 (4.82)	0.012 (0.45)	-	-	+	+
	SK-mel-28 (EMEM 10%FBS, 1%PS ATCC)	0.91 (16.72)	0.064 (0.65)	0.0523 (1.233)	0.00084 (0.031)	-	-	+	+
	A375 (DMEM 10%FBS, 1%PS ATCC)	0.15 (2.76)	0.061 (0.62)	0.0288 (0.679)	0.00059 (0.022)	-	-	+	+
	B16 (DMEM 10%FBS, 1%PS ATCC)			0.02 (0.48)	0.004 (0.11)	-	-	+	+

Table 11b

Type of cancer	Cell line name (medium, source)	BCA U/mL (µg/mL)	HAI U/mL (µg/mL)	rhArg U/mL (µg/mL)	ADI U/mL (µg/mL)	ARG	OTC	ASS	ASL
leukemia	HL60 (RPMI 10%FBS, 1%PS ATCC)			0.03 (0.679)	0.016 (0.591)	+	-	-	+
	K562 (RPMI 20%FBS, 1%PS ATCC)			0.06 (1.357)	0.003 (0.085)	-	-	+	-
	RPMI8226 (RPMI 10%FBS,			0.09 (2.036)	R				

	1%PS ATCC)								
	Jurkat (RPMI 10%FBS, 1%PS ATCC)	0.41 (7.54)		0.037 (0.86)	0.002 (0.074)				

Table 11c

Type of cancer	Cell line name (medium, source)	BCA U/mL (μg/m L)	HAI U/mL (μg/mL)	rhArg U/mL (μg/mL)	ADI U/mL (μg/mL)	ARG	OTC	ASS	ASL
colorectal	(WiDr DMEM 10%FBS, 1%PS ATCC)	0.215 (3.96)	0.075 (0.76)	0.038 (0.84)	0.035 (0.9)	+	-	+	-
	SW1116 (RPMI 10%FBS, 1%PS ATCC)	1.417 (20.98)	0.41 (4.18)	0.15 (3.394)	R	+	-	+	+
	HT29 (DMEM 10%FBS, 1%PS ATCC)	0.231 (4.24)		0.03 (0.679)	0.032 (0.83)	+	-	+	+
	HCT15 (RPMI 10%FBS, 1%PS ATCC)		0.63 (6.44)	0.083 (1.043)	R	+	-	+	+
pancreatic	Panc1 (DMEM 10%FBS, 1%PS ATCC)	0.263 (4.84)		0.09 (2.036)	0.049 (1.39)	-	-	+	+
	BxPC3 (EMEM	0.846 (15.54)		0.08 (1.809)	R	+	-	+	+

	10%FBS, 1%PS ATCC)								
	HPAFII (DMEM 10%FBS, 1%PS ATCC)			0.86 (19.35)	R	-	-	+	+

Table 11d

Type of cancer	Cell line name(medium , source)	BCA U/mL (μg/mL)	HAI U/mL (μg/mL)	rhArg U/mL (μg/mL)	ADI U/mL (μg/mL)	ARG	OTC	ASS	ASL
gastric	AGS (RPMI 10%FBS, 1%PS ATCC)	0.662 (12.17)		0.10 (2.262)	R	-	-	+	+
	MKN45 (RPMI 10%FBS, 1%PS Riken Cell bank, Japan)	0.798 (14.67)		0.79 (17.873)	R	-	-	+	+
	BCG-823 (RPMI 10%FBS, 1%PS Beijing Institute of Cancer Research)			0.11 (2.457)	R	-	-	+	+

Table 11e

Type of cancer	Cell line name(medium, source)	BCA U/mL (μg/mL)	HAI U/mL (μg/mL)	rhArg U/mL (μg/mL)	ADI U/mL (μg/mL)	ARG	OTC	ASS	ASL
----------------	--------------------------------------	------------------------	------------------------	--------------------------	------------------------	-----	-----	-----	-----

HCC (liver cancer)	PLC/PRF/5 (DMEM 10%FBS, 1%PS ATCC)	2.376 (43.67)	0.94 (9.56)	0.312 (7.07)	R	+	-	+	+
	Hep3B (DMEM 10%FBS, 1%PS ATCC)	9.1 (57.68)	0.29 (2.95)	0.65 (15.0)	R	+	-	+	+
	HepG2 (DMEM 10%FBS, 1%PS ATCC)	2.002 (36.79)	0.097 (0.99)	0.177 (4.00)	R	+	-	+	+
	Huh7 (DMEM 10%FBS, 1%PS ATCC)			1.59 (43)	R	+	-	+	+
	SK-HEP-1 (DMEM 10%FBS, 1%PS ATCC)	12.27 (77.79)	1.725 (6.05)	0.15 (4)	0.007 (0.2)	-	-	+	+
retinoblastoma	Y79 (RPMI 10%FBS, 1%PS ATCC)			0.5 (11.3)	R	-	-	+	+

Table 11f

Type of cancer	Cell line name (medium, source)	BCA U/mL (µg/mL)	HAI U/mL (µg/mL)	rhArg U/mL (µg/mL)	ADI U/mL (µg/mL)	ARG	OTC	ASS	ASL
lung	A549 (DMEM 10%FBS, 1%PS ATCC)	0.3294(2 .09)		0.035 (0.44)	0.011 (0.29)	-	-	-	+
Cervical	HeLa (DMEM 10%FBS, 1%PS	0.719 (13.21)	0.366 (3.72)	0.065 (0.82)	R	-	-	+	+

	ATCC)								
	ME180 (DMEM 10%FBS, 1%PS ATCC)	1.42 (26.16)	0.214 (2.18)	0.153 (1.93)	R	-	-	+	+
	CC3 (DMEM 10%FBS, 1%PS ATCC)	0.84 (15.50)		0.42 (5.29)	R	-	-	+	+
	SiHa (DMEM 10%FBS, 1%PS ATCC)	0.32 (5.84)	0.024 (0.24)	0.03 (0.38)	0.0025 (0.064)	-	-	-	+
	C-33A (DMEM 10%FBS, 1%PS ATCC)	0.19 (3.55)	0.033 (0.34)	0.058 (0.72)	0.0014 (0.036)	-	-	-	+

Table 11g

Type of cancer	Cell line name (medium, source)	BCA U/mL (µg/mL)	HAI U/mL (µg/mL)	rhArg U/mL (µg/mL)	ADI U/mL (µg/mL)	ARG	OTC	ASS	ASL
breast	MCF-7 (EMEM 10%FBS, 1%PS ATCC)	0.05 (0.91)		0.28 (6.36)	R	-	-	+	+
	ZR-75-1 (DMEM 10%FBS, 1%PS ATCC)			0.14 (3.18)	R	-	-	+	+
	Hs578T (DMEM 10%FBS, 1%PS, 10 ⁻⁶ g/ml insulin NCI)			3.75 (85.2)			-	+	+
	MDA-MB-231 (DMEM 10%FBS, 1%PS NCI)	0.22 (4.11)	0.273	0.44 (10.0)	0.16 (5.93)	-	-	+	+
	4T1	0.68	0.058	0.023 (0.29)	0.0007 (0.017)			L	
Prostate	PC3 (DMEM 10%FBS, 1%PS	0.263 (4.84)	0.40 (4.07)	0.08 (1.47)	0.0025 (0.064)	-	-	-	+

	ATCC)								
	LNCap	2.119	0.47 (4.78)	0.41	0.13				
	(EMEM 10%FBS, 1%PS	(38.94)		(5.16)	(3.34)				
	ATCC)								

[107] For Table 11, “+” = mRNA was detected by RT-PCR, indicating the corresponding gene is expressed; “-” = mRNA was not detected by RT-PCR, indicating the gene is not expressed; “R” indicates that the cell line is ADI-resistant and the IC₅₀ value cannot be estimated; and “L” indicates that the cell line has a relatively low level of ASS expression and therefore the cell line is still ADI-sensitive.

[108] While not wish to be bound by the following hypothesis and working models, applicants believe the following hypothesis and working models are consistent with the experimental data of the present invention and thus are useful guides for further utilization of the inventions disclosed herewith(also see FIG. 18) .

[109] *Hypothesis and working models explainning why OTC-negative cancer cells are arginase-sensitive but can be ADI-resistant.* When arginase is added in the culture medium or pegylated arginase is injected in the blood (in the body), arginine is converted into ornithine and urea by the arginase enzymatic reaction. Ornithine formed then passes into the cancer cells. Unlike normal cells, cancer cells grow rapidly and require much more arginine than normal cells for protein synthesis and other cellular processes. If the cancer cells are OTC-positive, ASS-positive and ASL-positive, ornithine can be recycled back into arginine. Therefore, cancer cells still have arginine and they are not arginine-deficient and cancer growth is not inhibited. On the other hand, cancer cells that are OTC-negative or ASS-negative or ASL-negative or any combination of these deficiencies or low expression level of any of these genes, the synthesis (or recycle) pathway from ornithine to arginine is blocked and therefore cancer cells are lack of arginine and cancer cell growth is thus inhibited and cancer cell death may occur.

[110] *Hypothesis and working models for liver cancer cells that are OTC-negative.* Model relating urea cycle gene expression and resistance towards pegylated arginine deiminase (ADI-PEG) and pegylated *Bacillus caldevelox* arginase (BCA-PEG20). Liver cancer cells express the urea cycle enzymes argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL) and arginase (ARG), but lack ornithine transcarbamylase (OTC). BCA-PEG20 in the bloodstream depletes arginine and produces ornithine, which enters the cell but fails to be recycled via the urea cycle owing to the absence of OTC. ADI-PEG converts arginine to citrulline, which can be readily converted back to arginine by ASS and ASL after uptake into liver cancer cells. Therefore, in this model, the liver cancer cells are sensitive to BCA-PEG20 treatment (inhibited by BCA-PEG20) but resistant to ADI-PEG treatment.

[111] *Hypothesis and working models for cancer cells that are OTC-negative.* Model relating gene expression in cancer cells and resistance towards pegylated arginine deiminase (ADI-PEG) and pegylated *Bacillus caldevelox* arginase (BCA-PEG20). For cancer cells that do not express arginase (ARG), cancer cells express the enzymes argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), but lack ornithine transcarbamylase (OTC). BCA-PEG20 in the bloodstream depletes arginine and produces ornithine, which enters the cell but fails to be recycled owing to the absence of OTC. ADI-PEG converts arginine to citrulline, which can be readily converted back to arginine by ASS and ASL after uptake into the cancer cells. Therefore, in this model, the cancer cells are sensitive to BCA-PEG20 treatment (inhibited by BCA-PEG20) but resistant to ADI-PEG treatment. This model can be applied to cancer cells in general.

Method of further enhance arginase activity by using Cobalt as metal cofactor

[112] The native metal cofactor of arginase is manganese (Mn^{2+}). It is surprisingly discovered by the present invention that replacing the manganese with cobalt dramatically enhances the enzyme's activity. Either *Bacillus caldovelox* arginase (BCA)

or the human arginase I (HAI) was expressed as described previously. The purification method was the same as described before except 10 mM of metal ion (CoSO_4 or MnSO_4) was added into the purified protein elution from Nickel affinity chromatography instead of added before Nickel affinity chromatography. Eluted fractions containing the arginase enzyme were incubated with 10 mM metal for 15 min at 50~55 °C, followed by filtration through a 0.45 μm syringe filter. Then the solution was exchanged with storage buffer by ultrafiltration.

[113] Diacetylmonoxine (DAMO) assay was used to determine the kinetic parameters of human arginase with different metal cofactors. All enzymatic reactions were carried out at pH 7.4. The results are shown in FIG. 16. The steady-state kinetics of recombinant human arginase I (HAI) or huArg substituted with Mn^{2+} or Co^{2+} were measured in sodium phosphate buffer pH 7.4, 25 °C. The K_m of HAI with Mn^{2+} (HAI Mn^{2+}) or huArg Mn^{2+} and HAI with Co^{2+} (HAI Co^{2+}) or huArg Co^{2+} are 1.83 mM and 0.19 mM respectively. Since the K_m value is improved about 10-fold in HAI Co^{2+} or huArg Co^{2+} , its specific activity is improved 10-fold and is a much more efficient drug to deplete arginine than HAI Mn^{2+} or huArg Mn^{2+} .

Enhancing arginase activity by further modifying genetic modification

[114] It is surprisingly discovered by the present invention that the position 20 of BCA can be substituted with other amino acids to improve enzyme activity. The 20th amino acid residue valine in the wild-type sequence was substituted with proline (or any other amino acids for example serine or glycine, which improves the specific activity of BCA) by site directed mutagenesis (for example codon GTT [valine] to CCG [proline]). The mutant genes were cloned, expressed and purified for detailed studies. An exemplary such mutant enzyme was made by replacing valine with proline, referred to as "BCA mutant V20P" or "bcArg V20P mutant". Steady-state kinetics of the BCA mutant V20P and BCA with Mn^{2+} or Co^{2+} were measured in sodium phosphate buffer pH 7.4, 25 °C and were shown in FIG. 17. The K_m values of

BCA mutant V20P with Mn^{2+} (BCA mutant V20P Mn^{2+}) and BCA mutant V20P with Co^{2+} (BCA mutant V20P Co^{2+}) are about 1.29 mM and 0.18 mM respectively. The K_m of BCA with Mn^{2+} (BCAWT Mn^{2+}) is about 3.2 mM. Therefore, the BCA mutant V20P with Co^{2+} as cofactor [$K_m = 0.18$ mM] is a much more efficient drug to deplete arginine than the BCA (BCAWT Mn^{2+}) [$K_m = 3.2$ mM].

In vitro cancer cell line studies using BCA mutant V20P

[115] Cell proliferation assay was conducted as follows.

[116] 2.5×10^3 Sk-mel-28 (EMEM), 5×10^3 HEK293 (EMEM), MCF-7 (EMEM), HCT-15 (RPMI), Hep3B (DMEM), PANC-1 (DMEM), Hela (DMEM) and A549 (DMEM) cells were seeded to each well of a 96-well plate in 100 μL culture medium and were allowed to adhere to the plate overnight. On the next day, the culture medium was replaced with medium containing different concentrations of BCA and BCA mutant V20P protein drug. 2×10^4 Jurkat (RPMI) floating cells were seeded to each well of a 96-well plate in 50 μL culture medium at the day of adding protein drug and different concentrations of protein drug in 50 μL were added directly to each well. The cells were allowed to incubate for an additional 3 days at 37°C in an atmosphere of 95% air/5% CO_2 . MTT cell proliferation assay (Invitrogen) was then performed to estimate the number of viable cells in the culture. In brief, 10 μL of 5 mg/mL of water-soluble MTT reagents was added to 100 μL culture medium and incubated at 37°C for 4 h. MTT is chemically reduced by cells into purple formazan, which is then dissolved by acidified SDS (0.01 N HCl in 10 % SDS) in tissue culture medium. Concentration of the cleavage product formazan was then measured by reading its absorbance with a spectrophotometer with a 570 nm filter. Cell proliferation data were expressed as a percentage of control. Non-linear regression was used to fit a sigmoidal dose response curve with Prism 4.0 (Graphpad Software), and the amount of protein drug needed to achieve 50% cell growth inhibition was defined as IC_{50} . The results are shown in Table 12. The corresponding enzymatic activities are shown

in Table 13.

Table 12: IC₅₀ of BCA and BCA mutant V20P in different kinds of cancer cells

		IC ₅₀ Value				Fold of Difference (BCA/ BCA mutant V20P)	
		BCA		BCA mutant V20P			
		(U/mL)	(mg/mL)	(U/mL)	(mg/mL)	(U/mL)	(mg/mL)
HCT-15	Colon	15.62	0.0916	7.34	0.0132	2.13	6.96
Jurkat	Leukemia	6.84	0.0401	0.90	0.0016	7.60	24.85
MCF-7	Breast	5.51	0.0323	2.87	0.0051	1.92	6.28
sk-mel-28	Melanoma	3.35	0.0197	1.52	0.0027	2.20	7.21
HEK293	Kidney	3.86	0.0226	3.40	0.0061	1.14	3.71
A549	Lung	2.67	0.0157	1.64	0.0029	1.63	5.32
Hep3B	Liver	9.42	0.0552	9.43	0.0169	1.00	3.27
Hela	Cervical	2.83	0.0166	1.37	0.0025	2.07	6.75
PANC-1	Pancreatic	1.20	0.0070	0.87	0.0016	1.38	4.51

Table 13: Specific activity of the proteins

	Protein concentration (mg/mL)	Specific activity (U/mg)	Enzyme activity (U/mL)
BCA	3.046	170.47	519.3
<u>BCA mutant</u> <u>V20P</u>	2.63	557.3	1465.7

[117] The results show that BCA mutant V20P is much more efficient in killing various types of cancer cells in *in vitro* drug efficacy studies.

[118] The scope of the claims should not be limited by the preferred embodiments set forth in the examples, but should be given the broadest interpretation consistent with the description as a whole.

What is claimed is:

1. A pharmaceutical composition for treating an arginine-dependent disease comprising
 - a PEG-arginase conjugate with arginase activity, said conjugate comprising a PEG moiety covalently attached to a genetically-modified human arginase I, the composition further comprising a pharmaceutically acceptable carrier, excipient, and/or auxiliary agent,
 - the genetic modification of the human arginase I forming an amino acid sequence having a single amino acid position for covalently attaching to the PEG moiety, the genetically-modified human arginase amino acid position being located to increase the PEG-arginase conjugate serum circulation half-life beyond the serum circulation half-life of pure unmodified human arginase I and to decrease the immunogenicity of the PEG-arginase conjugate below the immunogenicity of pure unmodified human arginase I,
 - wherein the genetically-modified human arginase I is SEQ. ID No. 6; said arginine-dependent disease is an arginine-dependent cancer or infection by a virus selected from the group consisting of HIV, hepatitis C virus, and hepatitis B virus.

2. A pharmaceutical composition for treating an arginine-dependent disease comprising
 - a PEG-arginase conjugate with arginase activity, said conjugate comprising a PEG moiety covalently attached to a genetically-modified *Bacillus caldovelox* arginase, the composition further comprising a pharmaceutically acceptable carrier, excipient, and/or auxiliary agent,
 - the genetic modification of the *Bacillus caldovelox* arginase forming an amino acid sequence having a single amino acid position for covalently attaching to the PEG moiety, the genetically-modified *Bacillus caldovelox* arginase amino acid position being located to increase the PEG-arginase conjugate serum circulation half-life beyond the serum circulation half-life of pure unmodified *Bacillus caldovelox* arginase and to decrease the immunogenicity of the PEG-arginase conjugate below the immunogenicity of pure unmodified *Bacillus caldovelox* arginase,
 - wherein the genetically-modified *Bacillus caldovelox* arginase is SEQ. ID No. 8; said arginine-dependent disease is an arginine-dependent cancer or infection by a virus selected from the group consisting of HIV, hepatitis C virus, and hepatitis B virus.

3. The pharmaceutical composition of claim 1 or 2, wherein the ratio of said PEG moiety to the genetically-modified human arginase I or genetically-modified *Bacillus caldovelox* arginase is one.
4. The pharmaceutical composition of claim 1, wherein the attachment position of the PEG moiety is Cys⁴⁵.
5. The pharmaceutical composition of claim 2, wherein the attachment position of the PEG moiety is Cys¹⁶¹.
6. The pharmaceutical composition of claim 1 or 2, wherein the PEG moiety is a single chain or branched chain polyethylene glycol.

FIG. 1A

```

ATGAGCGCCAAGTCCAGAACCATAGGGATTATTGGAGCTCCTTTCTCAAAGGGACAGCCA 60
CGAGGAGGGGGTGGAGAAGGCCCTACAGTATTGAGAAAGGCTGGTCTGCTTGAGAAACTT 120
AAAGAACAAGAGTGTGATGTGAAGGATTATGGGGACCTGCCCTTTGCTGACATCCCTAAT 180
GACAGTCCCTTTCAAATTGTGAAGAATCCAAGGTCTGTGGGAAAAGCAAGCGAGCAGCTG 240
GCTGGCAAGGTGGCAGAAGTCAAGAAGAACGGAAGAATCAGCCTGGTCTGGGCGGAGAC 300
CACAGTTTGGCAATTGGAAGCATCTCTGGCCATGCCAGGGTCCACCCCTGATCTTGGAGTC 360
ATCTGGGTGGATGCTCACACTGATATCAACACTCCACTGACAACCACAAGTGGAAACTTG 420
CATGGACAACCTGTATCTTTCCTCCTGAAGGAACATAAAGGAAAGATTCCCGATGTGCCA 480
GGATTCTCCTGGGTGACTCCCTGTATATCTGCCAAGGATATTGTGTATATTGGCTTGAGA 540
GACGTGGACCCTGGGGAACACTACATTTTGAAAACCTCTAGGCATTAAATACTTTTCAATG 600
ACTGAAGTGGACAGACTAGGAATTGGCAAGGTGATGGAAGAAACACTCAGCTATCTACTA 660
GGAAGAAAGAAAAGGCCAATTCATCTAAGTTTTGATGTTGACGGACTGGACCCATCTTTC 720
ACACCAGCTACTGGCACACCAGTCGTGGGAGGTCTGACATACAGAGAAGGTCTCTACATC 780
ACAGAAGAAATCTACAAAACAGGGCTACTCTCAGGATTAGATATAATGGAAGTGAACCCA 840
TCCCTGGGGAAGACACCAGAAGAAGTAACTCGAACAGTGAACACAGCAGTTGCAATAACC 900
TTGGCTTGTTTCGGACTTGCTCGGGAGGGTAATCACAAGCCTATTGACTACCTTAACCCA 960
CCTAAGTAA 969|

```

FIG. 1b

```

ATGAGCGCCAAGTCCAGAACCATAGGGATTATTGGAGCTCCTTTCTCAAAGGGACAGCCA 60
CGAGGAGGGGGTGGAGAAGGCCCTACAGTATTGAGAAAGGCTGGTCTGCTTGAGAAACTT 120
AAAGAACAAGAGTGTGATGTGAAGGATTATGGGGACCTGCCCTTTGCTGACATCCCTAAT 180
GACAGTCCCTTTCAAATTGTGAAGAATCCAAGGTCTGTGGGAAAAGCAAGCGAGCAGCTG 240
GCTGGCAAGGTGGCAGAAGTCAAGAAGAACGGAAGAATCAGCCTGGTCTGGGCGGAGAC 300
CACAGTTTGGCAATTGGAAGCATCTCTGGCCATGCCAGGGTCCACCCCTGATCTTGGAGTC 360
ATCTGGGTGGATGCTCACACTGATATCAACACTCCACTGACAACCACAAGTGGAAACTTG 420
CATGGACAACCTGTATCTTTCCTCCTGAAGGAACATAAAGGAAAGATTCCCGATGTGCCA 480
GGATTCTCCTGGGTGACTCCCTCTATATCTGCCAAGGATATTGTGTATATTGGCTTGAGA 540
GACGTGGACCCTGGGGAACACTACATTTTGAAAACCTCTAGGCATTAAATACTTTTCAATG 600
ACTGAAGTGGACAGACTAGGAATTGGCAAGGTGATGGAAGAAACACTCAGCTATCTACTA 660
GGAAGAAAGAAAAGGCCAATTCATCTAAGTTTTGATGTTGACGGACTGGACCCATCTTTC 720
ACACCAGCTACTGGCACACCAGTCGTGGGAGGTCTGACATACAGAGAAGGTCTCTACATC 780
ACAGAAGAAATCTACAAAACAGGGCTACTCTCAGGATTAGATATAATGGAAGTGAACCCA 840
TCCCTGGGGAAGACACCAGAAGAAGTAACTCGAACAGTGAACACAGCAGTTGCAATAACC 900
TTGGCTTCTTTCGGACTTGCTCGGGAGGGTAATCACAAGCCTATTGACTACCTTAACCCA 960
CCTAAGTAA 969

```

FIG. 1c

```

ATGAAGCCAATTTCAATTATCGGGGTTCCGATGGATTTAGGGGCAGACACG 50
CCGCGGCGTTGATATGGGGCCGAGCGCAATGCGTTATGCAGGCGTCATCG 100
AACGTCTGGAACGTCTTCATTACGATATTGAAGATTTGGGAGATATTCCG 150
ATTGGAAAAGCAGAGCGGTTGCACGAGCAAGGAGATTCACGGTTGCGCAA 200
TTTGAAAGCGGTTGCGGAAGCGAACGAGAACTTGCGGCGGCGGTTGACC 250
AAGTCGTTCAGCGGGGGCGATTTCGCTTGTTGGGCGGCGACCATAGC 300
ATCGCCATTGGCACGCTCGCCGGGGTGGCGAAACATTATGAGCGGCTTGG 350
AGTGATCTGGTATGACGCGCATGGCGACGTCAACACCGCGGAAACGTGCG 400
CGTCTGGAACATTTCATGGCATGCCGCTGGCGGCGAGCCTCGGGTTTGGC 450
CATCCGGCGCTGACGCAAATCGGCGGATACAGCCCCAAAATCAAGCCGGA 500
ACATGTCGTGTTGATCGGCGTCCGTTCCCTTGATGAAGGGGAGAAGAAGT 550
TTATTCGCGAAAAAGGAATCAAAATTTACACGATGCATGAGGTTGATCGG 600
CTCGGAATGACAAGGGTGATGGAAGAAACGATCGCCTATTTAAAAGAACG 650
AACGGATGGCGTTCATTTGTCGCTTGACTTGATGGCCTTGACCCAAGCG 700
ACGCACCGGGAGTCGGAACGCCTGTCATTGGAGGATTGACATACCGCGAA 750
AGCCATTTGGCGATGGAGATGCTGGCCGAGGCACAAATCATCACTTCAGC 800
GGAATTTGTCGAAGTGAACCCGATCTTGGATGAGCGGAACAAAACAGCAT 850
CAGTGGCTGTAGCGCTGATGGGGTCGTTGTTTGGTGAAAAACTCATGTAA 900

```

FIG. 1d

```

ATGAAGCCAATTTCAATTATCGGGGTTCCGATGGATTTAGGGGCAGACACG 50
CCGCGGCGTTGATATGGGGCCGAGCGCAATGCGTTATGCAGGCGTCATCG 100
AACGTCTGGAACGTCTTCATTACGATATTGAAGATTTGGGAGATATTCCG 150
ATTGGAAAAGCAGAGCGGTTGCACGAGCAAGGAGATTCACGGTTGCGCAA 200
TTTGAAAGCGGTTGCGGAAGCGAACGAGAACTTGCGGCGGCGGTTGACC 250
AAGTCGTTCAGCGGGGGCGATTTCGCTTGTTGGGCGGCGACCATAGC 300
ATCGCCATTGGCACGCTCGCCGGGGTGGCGAAACATTATGAGCGGCTTGG 350
AGTGATCTGGTATGACGCGCATGGCGACGTCAACACCGCGGAAACGTGCG 400
CGTCTGGAACATTTCATGGCATGCCGCTGGCGGCGAGCCTCGGGTTTGGC 450
CATCCGGCGCTGACGCAAATCGGCGGATACTGCCCCAAAATCAAGCCGGA 500
ACATGTCGTGTTGATCGGCGTCCGTTCCCTTGATGAAGGGGAGAAGAAGT 550
TTATTCGCGAAAAAGGAATCAAAATTTACACGATGCATGAGGTTGATCGG 600
CTCGGAATGACAAGGGTGATGGAAGAAACGATCGCCTATTTAAAAGAACG 650
AACGGATGGCGTTCATTTGTCGCTTGACTTGATGGCCTTGACCCAAGCG 700
ACGCACCGGGAGTCGGAACGCCTGTCATTGGAGGATTGACATACCGCGAA 750
AGCCATTTGGCGATGGAGATGCTGGCCGAGGCACAAATCATCACTTCAGC 800
GGAATTTGTCGAAGTGAACCCGATCTTGGATGAGCGGAACAAAACAGCAT 850
CAGTGGCTGTAGCGCTGATGGGGTCGTTGTTTGGTGAAAAACTCATGCAT 900
CACCATCACCATCACTAA 918

```

FIG. 2a

MSAKSRTIGIIGAPFSKGQPRGGVEEGPTVLRKAGLLEKLKEQECDVKDYGDLPFADIPN 60
 DSPFQIVKNPRSVGKASEQLAGKVAEVKKNGRISLVLGGDHSLAIGSISGHARVHPDLGV 120
 IWVDAHTDINTPLTTTSGNLHGQPVSFLLKELKGKIPDVPGFSWVTPCISAKDIVYIGLR 180
 DVDPGEHYILKTLGIIKYFSMTEVDRLGIGKVMEETLSYLLGRKKRPIHLSFDVDGLDPSF 240
 TPATGTPVVGGLTYREGLYITEEIIYKTGLLSGLDIMEVNPSLGKTPEEVTRTVNTAVAIT 300
 LACFGLAREGNHKPIDYLNPPK 322

FIG. 2b

MSAKSRTIGIIGAPFSKGQPRGGVEEGPTVLRKAGLLEKLKEQECDVKDYGDLPFADIPN 60
 DSPFQIVKNPRSVGKASEQLAGKVAEVKKNGRISLVLGGDHSLAIGSISGHARVHPDLGV 120
 IWVDAHTDINTPLTTTSGNLHGQPVSFLLKELKGKIPDVPGFSWVTPPSISAKDIVYIGLR 180
 DVDPGEHYILKTLGIIKYFSMTEVDRLGIGKVMEETLSYLLGRKKRPIHLSFDVDGLDPSF 240
 TPATGTPVVGGLTYREGLYITEEIIYKTGLLSGLDIMEVNPSLGKTPEEVTRTVNTAVAIT 300
 LASFGLAREGNHKPIDYLNPPK 322

FIG. 2c

MKPISIIIGVPMDLGQTRRGVDMGPSAMRYAGVIERLERLHYDIEDLGDIP 50
 IGKAERLHEQGDSRLRLNLKAVAEANEKLA^{AA}VDQVVQRGRFPLVLGGDHS 100
 IAIGTLAGVAKHYERLGVIWYDAHGDVNTAETSPSSGNIHGMPLAASLGFG 150
 HPALTQIGGYSPKIKPEHVVLIGVRSLDEGEKKFIREKGIKIYTMHEVDR 200
 LGMTRVMEETIAYLKERTDGVHLSLDLDGLDPSDAPGVGTPVIGGLTYRE 250
 SHLAMEMPLAEAQIIITSAEFVEVNPILDERNKTASVAVALMGSLFGEKLM 299|

FIG. 2d

MKPISIIIGVPMDLGQTRRGVDMGPSAMRYAGVIERLERLHYDIEDLGDIP 50
 IGKAERLHEQGDSRLRLNLKAVAEANEKLA^{AA}VDQVVQRGRFPLVLGGDHS 100
 IAIGTLAGVAKHYERLGVIWYDAHGDVNTAETSPSSGNIHGMPLAASLGFG 150
 HPALTQIGGYCPKIKPEHVVLIGVRSLDEGEKKFIREKGIKIYTMHEVDR 200
 LGMTRVMEETIAYLKERTDGVHLSLDLDGLDPSDAPGVGTPVIGGLTYRE 250
 SHLAMEMPLAEAQIIITSAEFVEVNPILDERNKTASVAVALMGSLFGEKLMH 300
HHHHH 305

FIG. 3a

atgagcgccaagtccagaaccatagggattattggagctccttttctcaaagggacagcca
 M S A K S R T I G I I G A P F S K G Q P
 cgaggaggggtggaagaaggccctacagtattgagaaaggctgggtctgcttgagaaactt
 R G G V E E G P T V L R K A G L L E K L
 aaagaacaagagtgtgatgtgaaggattatggggacctgcccttttgctgacatcccta
 K E Q E C D V K D Y G D L P F A D I P N
 gacagtcccttttcaaattgtgaagaatccaagggtctgtgggaaaagcaagcgagcagctg
 D S P F Q I V K N P R S V G K A S E Q L
 gctggcaagggtggcagaagtcaagaagaacggaagaatcagcctgggtgctggggcggagac
 A G K V A E V K K N G R I S L V L G G D
 cacagtttggcaattggaagcatctctggccatgccagggtccaccctgatcttggagtc
 H S L A I G S I S G H A R V H P D L G V
 atctgggtggatgctcacactgatatacaactccactgacaaccacaagtggaaacttg
 I W V D A H T D I N T P L T T T S G N L
 catggacaacctgtatcttttccctcctgaagggaactaaaagggaagattcccgatgtgcca
 H G Q P V S F L L K E L K G K I P D V P
 ggattctcctgggtgactccctctatatctgccaaaggatattgtgtatatattggcttgaga
 G F S W V T P S I S A K D I V Y I G L R
 gacgtggaccctggggaacactacattttgaaaactctaggcattaaataacttttcaatg
 D V D P G E H Y I L K T L G I K Y F S M
 actgaagtggacagactaggaattggcaagggtgatggaagaaacactcagctatctacta
 T E V D R L G I G K V M E E T L S Y L L
 ggaagaaagaaaaggccaattcatctaagttttgatgttgacggactggaccccatctttc
 G R K K R P I H L S F D V D G L D P S F
 acaccagctactggcacaccagtcgtgggaggtctgacatacagagaagggtctctacatc
 T P A T G T P V V G G L T Y R E G L Y I
 acagaagaaatctacaaaacagggtactctcaggattagatatataatggaagtgaacca
 T E E I Y K T G L L S G L D I M E V N P
 tccctggggaagacaccagaagaagtaactcgaacagtgaacacagcagttgcaataacc
 S L G K T P E E V T R T V N T A V A I T
 ttggcttcttttcggacttgctcgggaggggtaatcacaagcctattgactaccttaacca
 L A S F G L A R E G N H K P I D Y L N P
 cctaagtaa
 P K -

FIG. 3b

atgcatcaccatcaccatcacatgagcgcgaagtccagaaccatagggattattggagct
 M H H H H H H M S A K S R T I G I I G A
 cctttctcaaagggacagccacgaggaggggtggaagaaggccctacagtattgagaaag
 P F S K G Q P R G G V E E G P T V L R K
 gctgggtctgcttgagaaaacttaagaacaagagtgtgatgtgaaggattatggggacctg
 A G L L E K L K E Q E C D V K D Y G D L
 ccctttgctgacatccctaataacagtccttttcaaattgtgaagaatccaagggtctgtg
 P F A D I P N D S P F Q I V K N P R S V
 ggaaaagcaagcgcgagcagctgggctggcaagggtggcagaagtcaagaagaacggaagaatc
 G K A S E Q L A G K V A E V K K N G R I
 agcctgggtgctggggcggagaccacagtttggcaattggaagcatctctggccatgccagg
 S L V L G G D H S L A I G S I S G H A R
 gtccaccctgatcttgaggatcatctgggtggatgctcacactgatatacaactccactg
 V H P D L G V I W V D A H T D I N T P L
 acaaccacaagtggaaaacttgcacatggacaacctgtatctttcctcctgaagggaactaaaa
 T T T S G N L H G Q P V S F L L K E L K
 ggaaagattcccgatgtgccaggattctcctgggtgactccctctatatctgcccaaggat
 G K I P D V P G F S W V T P S I S A K D
 attgtgtatatattggcttgagagacgtggaccctgggggaacactacattttgaaaactcta
 I V Y I G L R D V D P G E H Y I L K T L
 ggcattaaataacttttcaatgactgaagtggacagactaggaattggcaagggtgatggaa
 G I K Y F S M T E V D R L G I G K V M E
 gaaacactcagctatctactaggaagaaagaaaaggccaattcatctaagttttgatgtt
 E T L S Y L L G R K K R P I H L S F D V
 gacggactggacccatctttcacaccagctactggcacaccagtcgtgggaggtctgaca
 D G L D P S F T P A T G T P V V G G L T
 tacagagaagggtctctacatcacagaagaaatctacaaaacagggtactctcaggatta
 Y R E G L Y I T E E I Y K T G L L S G L
 gatataatggaagtgaacccatccctgggggaagacaccagaagaagtaactcgaacagtg
 D I M E V N P S L G K T P E E V T R T V
 aacacagcagttgcaataaccttggcttcttttcggacttgctcgggaggggtaatcacaaag
 N T A V A I T L A S F G L A R E G N H K
 cctattgactaccttaacccacctaagtaa
 P I D Y L N P P K -

FIG. 3c

atgaagccaattttcaattatcgggggttccgatggatttagggcagacacgccgcggcggtt
 M K P I S I I G V P M D L G Q T R R G V
 gatatgggggccgagcgcgaatgcgttatgcaggcggtcatcgaacgtctggaacgtcttcat
 D M G P S A M R Y A G V I E R L E R L H
 tacgatattgaagattttgggagatattccgattggaaaagcagagcgggttgcacgagcaa
 Y D I E D L G D I P I G K A E R L H E Q
 ggagattcacggttgcgcgaatttgaaagcgggttgcggaagcgaacgagaaaacttgcggcg
 G D S R L R N L K A V A E A N E K L A A
 gcgggttgaccaagtcggttcagcggggggcgatttccgcttgtgttggggcggcgaccatagc
 A V D Q V V Q R G R F P L V L G G D H S
 atcgccattggcacgctcgccgggggtggcgaaacattatgagcgggttggagtgatctgg
 I A I G T L A G V A K H Y E R L G V I W
 tatgacgcgcgatggcgacgtcaacaccgcggaaacgtcgccgtctggaaacattcatggc
 Y D A H G D V N T A E T S P S G N I H G
 atgcccgttggcgggcgagcctcggggtttggccatccggcgctgacgcaaactcggcgggatac
 M P L A A S L G F G H P A L T Q I G G Y
 tgccccaaaatcaagccggaacatgtcgtgttgatcggcgtccggttcccttgatgaaggg
 C P K I K P E H V V L I G V R S L D E G
 gagaagaagttttattcgcgaaaaaggaatcaaaaatttacacgatgcatgaggttgatcgg
 E K K F I R E K G I K I Y T M H E V D R
 ctcggaatgacaagggtgatggaagaaacgatcgccctattttaaagaacgaacgggatggc
 L G M T R V M E E T I A Y L K E R T D G
 gttcattttgtcgcttgacttggatggccttgacccaagcgacgcaccggggagtgcggaacg
 V H L S L D L D G L D P S D A P G V G T
 cctgtcatttgaggattgacataccgcgaaagccattttggcgatggagatgctggccgag
 P V I G G L T Y R E S H L A M E M L A E
 gcacaaatcatcacttcagcgggaatttgtcgaagtgaacccgatcttggatgagcgggaac
 A Q I I T S A E F V E V N P I L D E R N
 aaaacagcatcagtggtgttagcgctgatgggggtcggttgtttggtgaaaaactcatgtaa
 K T A S V A V A L M G S L F G E K L M -

FIG. 3d

atgaagccaatttcaattatcgggggttccgatggatttagggcagacacgcccggcggtt
 M K P I S I I G V P M D L G Q T R R G V
 gatatggggccgagcgcaatgcgttatgcaggcgatcatcgaacgtctggaacgtcttcat
 D M G P S A M R Y A G V I E R L E R L H
 tacgatattgaagatttgggagatattccgatttgaaaagcagagcggttgccagagcaa
 Y D I E D L G D I P I G K A E R L H E Q
 ggagattcacgggttgccgcaatttgaaagcggttgccggaagcgaacgagaaacttgccggcg
 G D S R L R N L K A V A E A N E K L A A
 gcgggttgaccaagtcgttcagcggggggcgatttccgcttggtgttgggcccgcgaccatagc
 A V D Q V V Q R G R F P L V L G G D H S
 atcgccattggcacgctcgccgggggtggcgaaacattatgagcggcttgaggatgatctgg
 I A I G T L A G V A K H Y E R L G V I W
 tatgacgcgcgatggcgacgtcaacaccgcccgaacacgtcgccgtcttggaacattcatggc
 Y D A H G D V N T A E T S P S G N I H G
 atgccgctggcggcgagcctcggggttggccatccggcgctgacgcaaactcggcgggatac
 M P L A A S L G F G H P A L T Q I G G Y
 tgcccaaaaatcaagccggaacatgtcgtgttgatcggcgctccgttcccttgatgaaggg
 C P K I K P E H V V L I G V R S L D E G
 gagaagaagtttattcgcgaaaaaggaatcaaaaatttacacgatgcatgaggttgatcgg
 E K K F I R E K G I K I Y T M H E V D R
 ctcggaatgacaaggggtgatggaagaaacgatcgccctattttaaagaacgaacgggatggc
 L G M T R V M E E T I A Y L K E R T D G
 gttcatttgtcgcttgacttggtatggccttgacccaagcgcacccgggagtcgggaacg
 V H L S L D L D G L D P S D A P G V G T
 cctgtcattggaggattgacataccgcgaaagccatttggcgatggagatgctggccgag
 P V I G G L T Y R E S H L A M E M L A E
 gcacaaatcatcacttcagcgggaatttgtcgaagtgaacccgatcttggtatgagcgggaac
 A Q I I T S A E F V E V N P I L D E R N
 aaaacagcatcagtggtgtgtagcgtgatgggggtcggttggttgaaaaactcatgcat
 K T A S V A V A L M G S L F G E K L M **H**
caccatcaccatcactaa
H H H H H -



6xHis-tag encoding codons

FIG. 4a




FIG. 4b




FIG. 5a




FIG. 5b




FIG.6a1




FIG. 6a2




Fig. 6b1







Fig. 6b2

History Plot

BC-Arg_Glycerol_15012009(Finished) Selection: 1/15/2009 12:10:01 AM- 1/16/2009 11:22:26 AM











FIG. 7a


Lane 1: Low-range protein marker, Bio-Rad
Lane 2: Before chelating FF sepharose column (2.5 μ L)
Lane 3: Flowthrough (2.5 μ L)
Lane 4: Fraction A8 (10 μ L)
Lane 5: Fraction C2 (10 μ L)
Lane 6: Fraction C5 (10 μ L)
Lane 7: Fraction C8 (10 μ L)
Lane 8: Fraction C11 (10 μ L)
Lane 9: Fraction D11 (10 μ L)
Lane 10: Fraction D7 (10 μ L)

FIG. 7b




Lane 1: Low-range marker, Bio-Rad
Lane 2: Before chelating FF sepharose column (2.5 μ L)
Lane 3: Flowthrough (5 μ L)
Lane 4: Fraction C1 (10 μ L)
Lane 5: Fraction E7 (10 μ L)
Lane 6: Fraction F7 (10 μ L)
Lane 7: Fraction F6 (10 μ L)
Lane 8: Fraction F3 (10 μ L)
Lane 9: Fraction G2 (10 μ L)
Lane 10: Fraction G5 (10 μ L)

FIG. 8a



Lane 1: Low-range marker, Bio-Rad
Lane 2: Unpegylated human arginase I
Lane 3: Cys ⁴⁵ pegylated human arginase I

FIG. 8b



Lane 1: Low-range marker, Bio-Rad
Lane 2: Unpegylated <i>Bacillus caldovelox</i> arginase
Lane 3: Cys ¹⁶¹ pegylated <i>Bacillus caldovelox</i> arginase

FIG. 9a




FIG. 9b




FIG. 10a




FIG. 10b




FIG. 11a




FIG. 11b




FIG. 12a




FIG. 12b




FIG. 13




FIG. 14




FIG. 15

Fig. 15 Cytotoxicity of Cys⁴⁵ pegylated human arginase I (HAI-PEG20)




FIG. 16




FIG. 17




FIG. 18

